<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>High-grade gastroenteropancreatic neuroendocrine neoplasms</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">High-grade gastroenteropancreatic neuroendocrine neoplasms</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">High-grade gastroenteropancreatic neuroendocrine neoplasms</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Halfdan Sorbye, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan R Strosberg, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard M Goldberg, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 01, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H63417262"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The classification and nomenclature of neuroendocrine neoplasms (NEN) arising in the pancreas and gastrointestinal (GI) tract have evolved over the last two decades. High-grade NEN of the GI tract and pancreas are a heterogeneous group of aggressive malignancies. Most are poorly differentiated high-grade neuroendocrine carcinomas (NEC) with a high propensity for distant metastases and an ominous prognosis, even when clinically localized. A subset are high grade by proliferative or mitotic rate but demonstrate well-differentiated histology (well-differentiated grade 3 [G3] neuroendocrine tumors [NET]) and have a prognosis that is midway between the high-grade poorly differentiated NEC and well-differentiated grade 2 NET, which are more indolent. (See  <a class="medical medical_review" href="/z/d/html/14247.html" rel="external">"Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system", section on 'Classification and terminology'</a>.)</p><p>This topic review will cover the epidemiology, clinical features, diagnosis, staging, prognosis, and treatment of high-grade gastroenteropancreatic (GEP) NEN. A more in-depth discussion of the pathology and classification of NEN arising in the digestive system; clinical characteristics, localization, and staging of GI tract NEN and pancreatic NEN; the presentation, prognosis, and biochemical monitoring of metastatic GEP NEN; treatment options, including both local therapies and systemic therapies, for well-differentiated metastatic GEP NET; and issues related to presentation, evaluation, and treatment of NEN of unknown primary site are presented elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14247.html" rel="external">"Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2613.html" rel="external">"Clinical characteristics of well-differentiated neuroendocrine (carcinoid) tumors arising in the gastrointestinal and genitourinary tracts"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2612.html" rel="external">"Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2194.html" rel="external">"Metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15045.html" rel="external">"Surgical resection of sporadic pancreatic neuroendocrine tumors"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2615.html" rel="external">"Staging, treatment, and post-treatment surveillance of non-metastatic, well-differentiated gastrointestinal tract neuroendocrine (carcinoid) tumors"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16105.html" rel="external">"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16901.html" rel="external">"Metastatic well-differentiated gastrointestinal neuroendocrine (carcinoid) tumors: Systemic therapy options to control tumor growth"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/90664.html" rel="external">"Metastatic well-differentiated pancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4876.html" rel="external">"Neuroendocrine neoplasms of unknown primary site"</a>.)</p><p></p><p class="headingAnchor" id="H463615344"><span class="h1">CLASSIFICATION AND BIOLOGIC BEHAVIOR</span><span class="headingEndMark"> — </span>In 2006 and 2007, the European Neuroendocrine Tumor Society (ENETS) proposed a grading scheme for neuroendocrine neoplasms (NEN) of the digestive tract, which was later endorsed by the American Joint Committee on Cancer for its tumor, node, metastasis (TNM) staging classification. (See <a class="local">'Staging system'</a> below and  <a class="medical medical_review" href="/z/d/html/14247.html" rel="external">"Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system", section on 'Classification and terminology'</a>.)</p><p>The 2010 World Health Organization (WHO) classification of tumors of the gastrointestinal (GI) tract, liver, and pancreas also endorsed the ENETS grading scheme for NEN of the digestive tract, separating well-differentiated neuroendocrine tumors (NET) into low-grade (grade 1 [G1]) and intermediate-grade (grade 2 [G2]) categories [<a href="#rid1">1-3</a>]. (See  <a class="medical medical_review" href="/z/d/html/14247.html" rel="external">"Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system", section on '2010 and 2019 World Health Organization classification'</a>.)</p><p>The 2010 WHO classification equated poorly differentiated histology with high tumor grade; however, an increasing number of studies have challenged the assumption that poorly differentiated histology and high tumor grade are equivalent [<a href="#rid4">4-10</a>]. While it is true that nearly all poorly differentiated cancers have a high proliferation rate, not all grade 3 (G3) tumors are poorly differentiated. A subset of patients with NEN that appear histologically well differentiated is associated with Ki-67 proliferation indices &gt;20 percent, usually in the 20 to 55 percent range [<a href="#rid11">11,12</a>]. The most recent 2019 WHO classification of NEN of the digestive system now recognizes a category of high-grade but well-differentiated GEP NEN  (<a class="graphic graphic_table graphicRef122325" href="/z/d/graphic/122325.html" rel="external">table 1</a>) [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/z/d/html/14247.html" rel="external">"Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system", section on 'High-grade, well-differentiated neoplasms'</a>.)</p><p class="headingAnchor" id="H92260254"><span class="h2">Poorly differentiated neuroendocrine carcinomas</span><span class="headingEndMark"> — </span>In general, all high-grade poorly differentiated GEP neuroendocrine carcinomas (NEC) have an aggressive natural history that is frequently characterized by early, widespread metastases. Patients who present with locoregional disease may be cured by aggressive therapy; however, many relapse, and then the overall prognosis is poor. Similar to their lung counterparts, GEP NEC have been traditionally divided into large cell and small cell subtypes based on the morphologic features of the individual tumor cells (see  <a class="medical medical_review" href="/z/d/html/4603.html" rel="external">"Pathology of lung malignancies", section on 'Neuroendocrine tumors'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Small cell carcinoma was the first category described in both the lung and GI tract, and for this reason, most of the published literature on extrapulmonary poorly differentiated NEC (which can arise in sites other than the GI tract and pancreas) is focused on small cell carcinoma. (See  <a class="medical medical_review" href="/z/d/html/2979.html" rel="external">"Small cell carcinoma of the bladder"</a> and  <a class="medical medical_review" href="/z/d/html/13930.html" rel="external">"Small cell neuroendocrine carcinoma of the cervix"</a> and  <a class="medical medical_review" href="/z/d/html/4882.html" rel="external">"Extrapulmonary small cell cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>By contrast, the large cell subtype [<a href="#rid14">14-16</a>], which seems to constitute approximately 60 percent of GEP NEC cases [<a href="#rid17">17</a>], has been less frequently reported [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/z/d/html/14247.html" rel="external">"Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system", section on 'Poorly differentiated neoplasms'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most series report no apparent difference in prognosis between the large cell and small cell subtypes of poorly differentiated GEP NEC [<a href="#rid14">14,15,17-20</a>]; however, data from one large Dutch cancer registry showed better survival for large cell subtypes of all stages [<a href="#rid21">21</a>].</p><p></p><p>Given some similarities, treatment paradigms for poorly differentiated extrapulmonary NEC, including those arising in the GI tract, have largely paralleled those established for small cell lung cancer (SCLC). (See  <a class="medical medical_review" href="/z/d/html/4634.html" rel="external">"Limited-stage small cell lung cancer: Initial management"</a> and  <a class="medical medical_review" href="/z/d/html/4882.html" rel="external">"Extrapulmonary small cell cancer"</a>.)</p><p>However, there are differences, as SCLC is more strongly associated with smoking, brain metastases are more common, and objective response rates to platinum-based chemotherapy are generally higher [<a href="#rid22">22-26</a>]. There are also several differences in the mutational frequencies: GEP NEC seems to have a lower rate of mutations in the <em>TP53</em> gene and alterations in expression of the <em>RB1</em> gene than SCLC, and other genes are more frequently altered [<a href="#rid27">27-29</a>]. One-half of small cell pancreatic NEC have <em>KRAS</em> mutations, in contrast to SCLC where <em>KRAS</em> mutations are rarely found [<a href="#rid28">28,30</a>]. On the other hand, SCLC has a greater than 90 percent incidence of loss of <em>RB1</em> gene function, compared with 60 percent in pancreatic small cell NEC. (See  <a class="medical medical_review" href="/z/d/html/4628.html" rel="external">"Pathobiology and staging of small cell carcinoma of the lung"</a> and  <a class="medical medical_review" href="/z/d/html/4634.html" rel="external">"Limited-stage small cell lung cancer: Initial management"</a>.)</p><p class="headingAnchor" id="H1612598"><span class="h2">High-grade well-differentiated tumors</span><span class="headingEndMark"> — </span>The distribution of NET G3 relative to poorly differentiated NEC is difficult to ascertain. The only prospective data come from the Pronet study, a one-year prospective epidemiologic study among French pathologists to assess the characteristics of newly diagnosed NEN, including a review of the diagnostic pathology [<a href="#rid31">31</a>]. Of the 1340 cases that were collected, 104 were G3, of which 21 (20 percent) were described by the participating pathologists as well or moderately differentiated.</p><p>There are differences in the presentation of NET G3 as compared with NEC, including primary tumor location, percentage with elevated tumor markers, uptake on somatostatin receptor scintigraphy, and Ki-67 index; these are outlined in the table  (<a class="graphic graphic_table graphicRef111374" href="/z/d/graphic/111374.html" rel="external">table 2</a>) [<a href="#rid7">7,10-12,31,32</a>]. Given these characteristics, among patients newly diagnosed with a high-grade NEN, the possibility of a NET G3 should especially be considered when the Ki-67 index is between 20 and 55 percent, if somatostatin receptor imaging is positive, and when a pancreatic primary is present.</p><p>The clinical behavior of these tumors appears to differ from that of high-grade poorly differentiated NEC. Median survival of patients with NET G3 tumors is more than double that of patients with poorly differentiated high-grade neoplasms; in three studies, the differences were 40 versus 17 months, 32 versus 15 months, and, among cases with metastatic disease, 33 versus 11 months [<a href="#rid7">7,33,34</a>]. As such, the clinical behavior of NET G3 tumors appears to be in between poorly differentiated NEC and intermediate-grade (G2) well-differentiated NET [<a href="#rid10">10</a>].</p><p>These data underscore the importance of distinguishing between NET G3 and poorly differentiated NEC. Moreover, there are significant differences with respect to treatment response. Large retrospective analyses demonstrate that tumors with Ki-67 rates &lt;55 percent respond poorly to the <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>/carboplatin-based regimens that are used for poorly differentiated NEC [<a href="#rid35">35</a>]. (See <a class="local">'High-grade, well-differentiated tumors (NET G3)'</a> below.)</p><p class="headingAnchor" id="H463615367"><span class="h1">EPIDEMIOLOGY AND RISK FACTORS</span><span class="headingEndMark"> — </span>The incidence of high-grade GEP NEN is difficult to establish given the fact that many international cancer registries that include NEN do not collect information on tumor grade [<a href="#rid21">21,36-39</a>]. However, the available data indicate that high-grade neoplasms are very rare:</p><p class="bulletIndent1"><span class="glyph">●</span>In the Netherlands Cancer Registry, from 2000 to 2010, the annual incidence of GEP neuroendocrine carcinoma (NEC) was estimated to be 0.54 per 100,000 inhabitants. Large cell GEP NEC was twice as common as small cell GEP NEC (incidence of 0.36 versus 0.18 per 100,000 inhabitants) [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the United States, based upon data from the Surveillance, Epidemiology, and End Results (SEER) program, the incidence of colorectal NEC was 0.2 per 100,000 inhabitants [<a href="#rid36">36</a>]. In a separate analysis of over 162,000 cases of NEC reported to SEER between 1973 and 2012, the colon, rectum, and anal canal accounted for 41 percent of the NEC arising within the gastrointestinal tract, while the upper gastrointestinal tract and the pancreas accounted for 23 and 20 percent, respectively [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In Norway, between 1993 and 2010, the incidence of high-grade pancreatic NEN was 0.04 per 100,000 population and stable over time [<a href="#rid40">40</a>].</p><p></p><p>In the last two decades, the incidence of high-grade GEP NEN seems to be increasing [<a href="#rid17">17,21,41</a>]. As an example, in the Netherlands Cancer Registry report, there was an increase in incidence of GEP NEC over the last two decades from 0.3 to 0.54 per 100,000 [<a href="#rid21">21</a>]. However, this trend is difficult to interpret since it has coincided with the changes in the nomenclature and classification of GEP NEC resulting in more awareness of the entity among pathologists, epidemiologists, and oncologists, and more precise classification [<a href="#rid6">6,17</a>]. (See <a class="local">'Classification and biologic behavior'</a> above.)</p><p>In most series, incidence rates are similar in males and females. However, at certain sites (ie, esophagus, stomach), there is a male predominance [<a href="#rid42">42-44</a>].</p><p class="headingAnchor" id="H1610437"><span class="h2">Risk factors</span><span class="headingEndMark"> — </span>Risk factors for high-grade GEP NEN are not well elucidated. Some reports note an association with smoking, but not as tight an association as with small cell lung cancer [<a href="#rid21">21,26,45</a>]; more data are required to determine how tobacco exposure affects risk. Studies have also suggested a prior history of achalasia, gastroesophageal reflux disease, or Barrett metaplasia can be associated with esophageal NEC, while colonic adenomas and ulcerative colitis may similarly increase risk for colorectal NEC [<a href="#rid45">45,46</a>].</p><p>The presence of a well-differentiated GEP NET is not a defined risk factor for GEP NEC. It is believed that NEC generally do not arise from well-differentiated NET, since usually GEP NEC and NET are not found together on pathologic exam [<a href="#rid6">6,45</a>]. While low-grade NET often develop high proliferative activity during the course of metastatic disease and well-differentiated NET may have a morphologically apparent high-grade component [<a href="#rid47">47</a>], transformation from a well-differentiated NET into a truly poorly differentiated phenotype is uncommon [<a href="#rid47">47</a>]. (See  <a class="medical medical_review" href="/z/d/html/14247.html" rel="external">"Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system", section on 'High-grade, well-differentiated neoplasms'</a>.)</p><p class="headingAnchor" id="H463615379"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>The presenting symptoms of high-grade (grade 3 [G3]) GEP NEN are quite variable and depend upon the site of the primary tumor and whether or not metastatic disease is present:</p><p class="bulletIndent1"><span class="glyph">●</span>Within the digestive tract, the most common primary tumor locations for neuroendocrine carcinoma (NEC) are the esophagus, stomach, pancreas, and large bowel (including the anal canal) [<a href="#rid17">17,32,35,45,48-50</a>]. (See  <a class="medical medical_review" href="/z/d/html/4882.html" rel="external">"Extrapulmonary small cell cancer"</a>.)</p><p></p><p class="bulletIndent1">Within the large bowel, the majority of lesions are distal; in a review of 75 cases, the most common site of origin was the rectum, followed by the cecum, sigmoid colon, transverse colon, and ascending colon (38, 27, 17, 12, and 6 percent, respectively) [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1">For well-differentiated neuroendocrine tumors (NET) G3, the primary tumor is most frequently located in the pancreas [<a href="#rid7">7,10-12,31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Presenting symptoms may include both generalized systemic symptoms (such as anorexia, fatigue, and weight loss) and site-specific symptoms (such as focal pain, melena, hematochezia, dysphagia, nausea, emesis, bowel obstruction, or jaundice). If the initial clinical manifestations are due to locoregional disease, the presenting symptoms may be indistinguishable from other tumors arising in the same site. As an example, the symptoms of esophageal small cell carcinoma typically reflect the presence of a mass. When the tumor is localized, progressive dysphagia and indigestion are common complaints; weight loss and cachexia due to anorexia and decreased caloric intake may also be seen [<a href="#rid51">51,52</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nearly all GEP NEC are nonsecretory [<a href="#rid32">32,53-55</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Given the aggressive nature of GEP NEC, most patients have metastatic disease at the time of presentation [<a href="#rid18">18,32,55</a>]. An analysis using Surveillance, Epidemiology, and End Results data of 2546 cases of GEP NEC G3 revealed that distant disease was present at initial diagnosis in 57 percent of cases [<a href="#rid56">56</a>]. The scarce data available for NET G3 suggest also a high percentage of metastatic disease (62 to 70 percent) at diagnosis [<a href="#rid11">11,28,57</a>]. Symptoms related to distant metastases may include right upper quadrant pain from liver metastases, bone pain, respiratory complaints, and rarely, central nervous system symptoms from brain metastases.</p><p></p><p class="bulletIndent1">However, in contrast to pulmonary small cell lung cancer, the risk of brain metastases is lower [<a href="#rid25">25,58,59</a>].</p><p></p><p class="headingAnchor" id="H463615385"><span class="h1">DIAGNOSIS AND STAGING</span><span class="headingEndMark"> — </span>The diagnosis of a high-grade GEP NEN requires histologic examination of tumor material from a biopsy or excised specimen. The diagnostic workup of a GEP neuroendocrine carcinoma (NEC) differs from the diagnostic evaluation of a well-differentiated neuroendocrine tumor (NET). The roles of both tumor markers (ie, serum chromogranin A [CgA], serum/urinary 5-hydroxyindoleacetic acid [5-HIAA]) and somatostatin receptor imaging are usually minor unless the patient is suspected of having or has a well-differentiated high-grade (grade 3 [G3]) NET. By contrast, positron emission tomography (PET) scanning using fluorodeoxyglucose (FDG-PET) is of greater utility with NEC.</p><p class="headingAnchor" id="H463615391"><span class="h2">Pathologic diagnosis</span><span class="headingEndMark"> — </span>The hallmark of neuroendocrine cells is the production of abundant neurosecretory granules, as reflected in the strong and diffuse immunohistochemical expression of neuroendocrine markers such as synaptophysin and chromogranin. All neoplasms with neuroendocrine differentiation should be assessed for grade and extent of differentiation. Differentiation refers to the resemblance of the tumor histology to its normal counterparts, whereas grade describes the proliferative activity of the tumor, as measured by mitotic rate or Ki-67 rate  (<a class="graphic graphic_table graphicRef122325" href="/z/d/graphic/122325.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/14247.html" rel="external">"Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system", section on 'Morphology and immunohistochemistry'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>NEC versus G3 NET</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>GEP NEC less closely resembles nonneoplastic neuroendocrine cells, having a more sheet-like or diffuse architecture, irregular nuclei, and less cytoplasmic granularity  (<a class="graphic graphic_figure graphicRef98815" href="/z/d/graphic/98815.html" rel="external">figure 1</a>). There are two distinct histologic entities: small cell and large cell NEC  (<a class="graphic graphic_figure graphicRef98814" href="/z/d/graphic/98814.html" rel="external">figure 2</a>) [<a href="#rid13">13</a>]. Small cell carcinomas are composed of small- to medium-sized, round to oval cells with scant cytoplasm and hyperchromatic nuclei with indistinct nucleoli. The large cell subtype is composed of large cells with vesicular nuclei showing prominent nucleoli and abundant eosinophilic cytoplasm. In both cases, the tumor cells grow in sheets, forming nest-like structures, often with large confluent areas of necrosis [<a href="#rid60">60</a>]. Perineural and vascular invasions are frequently observed.</p><p></p><p class="bulletIndent2">By contrast, GEP NET G3 more closely resemble nonneoplastic neuroendocrine cells, with characteristic "organoid" arrangements of the tumor cells with solid/nesting, trabecular, gyriform or sometimes glandular patterns. The cells are relatively uniform, and they have round to oval nuclei, coarsely stippled chromatin, and finely granular cytoplasm.</p><p></p><p class="bulletIndent2">Histologically, when a pathologist is assessing a high-grade NEN, morphologic features have not always been reliable in separating a well-differentiated NET from a poorly differentiated NEC. However, more recent data suggests that this organoid growth pattern, in conjunction with a capillary network in direct contact to tumor cells, and absence of desmoplastic stroma can help to separate NET G3 from NEC [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>There is no Ki-67 index cutoff within the G3 range (&gt;20 percent) that sharply separates these two neoplasms; a high Ki-67 (&gt;55 percent) usually points to NEC, but rates in the 20 to 55 percent range can be seen with either NET or NEC. On the other hand, a mitotic rate greater than 20 per 10 high-powered fields usually indicates a NEC, since most NET fall into the G3 range solely based on Ki-67 index. This subject is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/14247.html" rel="external">"Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system", section on 'Issues related to assessing grade'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Immunohistochemical staining may help with this distinction in difficult cases. (See <a class="local">'Immunohistochemistry'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mixed neuroendocrine/nonneuroendocrine neoplasms</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Some GEP NEC may contain nonneuroendocrine components, including adenocarcinoma, signet ring cell carcinoma, and more rarely, squamous cell cancer. If the neoplasm consists of a neuroendocrine component and a gland-forming component both exceeding 30 percent, the new 2019 World Health Organization (WHO) classification defines it as a mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN) [<a href="#rid61">61,62</a>].</p><p></p><p>The origin of these mixed tumors is thought to be a totipotent stem cell present in the submucosa that can differentiate into various cell lines [<a href="#rid51">51,63,64</a>]. Clinical management of metastatic disease is controversial as there are only retrospective series with limited sample sizes. As a result, there is significant variability as to initial systemic treatment of metastatic MiNEN (ie, use of a NEC-type regimen [platinum/<a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a>] versus an adenocarcinoma regimen [fluoropyrimidine backbone based on primary tumor site]) [<a href="#rid65">65</a>]. Some have suggested a NEC-type regimen for those with a high-grade MiNEN (G3 poorly differentiated NEC as the neuroendocrine component) and an adenocarcinoma-type regimen for all others who have a well-differentiated NEN component [<a href="#rid66">66</a>].</p><p class="headingAnchor" id="H1612671"><span class="h3">Immunohistochemistry</span><span class="headingEndMark"> — </span>Immunohistochemical staining for synaptophysin and CgA is used to determine if a tumor has neuroendocrine features. Many GEP NEC will stain for both synaptophysin and CgA, but whereas synaptophysin is almost always positive, CgA may be only focally positive or negative [<a href="#rid1">1,11,35,67</a>]. Generally, the presence of a small cell histology defines a NEC, whereas for cases in which the histology is non-small cell, synaptophysin should be present in addition to a neuroendocrine morphology. The specificity and clinical utility of immunohistochemical staining for other neuroendocrine markers, such as neuron-specific enolase, protein gene product 9.5, and CD56, are uncertain [<a href="#rid68">68</a>] and they are not used.</p><p>Immunohistochemical staining may also be helpful for differentiating NEC from NET G3. As an example, pancreatic NET G3 show loss of <em>DAXX</em> and <em>ATRX</em> in roughly one-half of cases, similar to pancreatic NET grade 1 (G1) and grade 2 (G2), whereas loss of <em>RB1</em> expression or abnormality of p53 expression supports a diagnosis of NEC [<a href="#rid69">69</a>]. (See  <a class="medical medical_review" href="/z/d/html/14247.html" rel="external">"Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system", section on 'High-grade, well-differentiated neoplasms'</a>.)</p><p class="headingAnchor" id="H3426672471"><span class="h2">Radiographic studies</span><span class="headingEndMark"> — </span>The diagnostic workup for a GEP NEN G3 is typically accomplished by cross-sectional imaging (contrast-enhanced computed tomography [CT] and/or magnetic resonance imaging scans), which typically include imaging of the chest, abdomen, and pelvis.</p><p>For NEC, we often perform integrated PET-CT scanning using fluorodeoxyglucose (FDG-PET/CT), which is positive in most cases (92 percent in one study [<a href="#rid32">32</a>]). FDG-PET/CT is especially useful for patients after radical surgery for apparently localized disease before start of adjuvant therapy, as many cases will have developed metastatic disease. Routine brain imaging in patients lacking neurologic symptoms is not recommended because GEP NEC are associated with a lower incidence of brain metastases than small cell lung cancer. (See <a class="local">'Clinical presentation'</a> above and  <a class="medical medical_review" href="/z/d/html/2612.html" rel="external">"Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms"</a>.)</p><p>For patients with NEC, somatostatin receptor-based imaging (eg, with <a class="drug drug_general" data-topicid="108440" href="/z/d/drug information/108440.html" rel="external">Ga-68 DOTATATE</a>, Ga-68 DOTATOC, or Cu-64 DOTATATE integrated PET/CT) is usually not helpful; it is negative in over one-half of cases [<a href="#rid32">32,70</a>]. However, somatostatin receptor-based imaging, rather than FDG-PET scanning, is reasonable for NET G3. Two studies have directly compared somatostatin receptor imaging in G3 NET with that in NEC: in one study, imaging was positive in 88 percent of NET G3 versus 40 percent of NEC cases [<a href="#rid11">11</a>]; in the second analysis, imaging was positive in 87 percent of NET G3 versus 50 percent of NEC cases [<a href="#rid71">71</a>].</p><p class="headingAnchor" id="H89616442"><span class="h2">Tumor markers</span><span class="headingEndMark"> — </span>Well-differentiated GEP NET have the capacity to make and secrete bioactive amines and peptides, both hormonal (eg, serotonin) and nonhormonal (eg, chromogranin A [CgA]). (See  <a class="medical medical_review" href="/z/d/html/130551.html" rel="external">"Overview of tumor biomarkers in gastroenteropancreatic neuroendocrine tumors"</a>.)</p><p>However, the role of serial assay of tumor markers such as CgA in GEP NEN G3 is not well established. Serum levels of CgA can be elevated in some patients, including those with NEC [<a href="#rid11">11,32,35</a>]. In one series of 253 patients with a GEP NEC, 46 percent had elevated levels of CgA at diagnosis [<a href="#rid32">32</a>]. However, it is not clear that radiographically assessed disease burden is paralleled by changes in the CgA, even if it is initially elevated. Given that radiographic scans usually show progression and response quite clearly in this disease, and the fact that conventional tumor markers such as CgA are rarely useful (even for low-grade NET), we do not routinely assay CgA before or during treatment in patients with NEN G3. Measurement of serum/urine levels of the serotonin metabolite 5-HIAA is not useful for high-grade NEN or NEC given the lack of serotonin secretion in these patients [<a href="#rid35">35</a>]. (See  <a class="medical medical_review" href="/z/d/html/130551.html" rel="external">"Overview of tumor biomarkers in gastroenteropancreatic neuroendocrine tumors", section on 'Role of nonhormonal tumor markers in clinical practice'</a> and  <a class="medical medical_review" href="/z/d/html/130551.html" rel="external">"Overview of tumor biomarkers in gastroenteropancreatic neuroendocrine tumors", section on 'Serotonin and 5-hydroxyindoleacetic acid (5-HIAA)'</a>.)</p><p class="headingAnchor" id="H89618018"><span class="h2">Staging system</span><span class="headingEndMark"> — </span>There is no universally agreed-upon staging system for GEP NEN G3:</p><p class="bulletIndent1"><span class="glyph">●</span>In 2006 and 2007, the European Neuroendocrine Tumor Society (ENETS) proposed a staging scheme similar to most other types of epithelial neoplasms for NEN of the digestive tract, which was accompanied by a histologic grading system that could be applied to all tumor stages [<a href="#rid72">72,73</a>]. The ENETS proposal stages poorly differentiated NEC in the same way as well-differentiated NET.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The WHO has endorsed staging NEN of both the pancreas and tubular gastrointestinal tract using a tumor, node, metastasis (TNM)-based system as is used by the American Joint Committee on Cancer (AJCC) [<a href="#rid74">74,75</a>]. The current eighth edition of the combined AJCC/Union for International Cancer Control TNM staging manual, which reflects a modification of the ENETS proposal [<a href="#rid76">76</a>], includes separate TNM staging systems for well-differentiated NET of appendix, pancreas, stomach, small bowel/ampulla of Vater, and colorectal primary sites [<a href="#rid77">77</a>]. However, in contrast to the ENETS recommendation [<a href="#rid72">72,73</a>], poorly differentiated NEC are staged using the staging classifications for adenocarcinomas at the individual primary tumor sites, not as well-differentiated NET. (See  <a class="medical medical_review" href="/z/d/html/2615.html" rel="external">"Staging, treatment, and post-treatment surveillance of non-metastatic, well-differentiated gastrointestinal tract neuroendocrine (carcinoid) tumors"</a> and  <a class="medical medical_review" href="/z/d/html/2612.html" rel="external">"Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms"</a>.)</p><p></p><p class="headingAnchor" id="H150863588"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>Well-differentiated GEP NET can usually be distinguished from poorly differentiated GEP NEC G3 by their morphologic appearance and lower proliferative indices  (<a class="graphic graphic_table graphicRef122325" href="/z/d/graphic/122325.html" rel="external">table 1</a>). However, the histologic diagnosis of a poorly differentiated NEC needs to be supported by immunohistochemical evidence of neuroendocrine differentiation (ie, staining for chromogranin and/or synaptophysin) to avoid possible misdiagnosis with the more frequent poorly differentiated adenocarcinomas (including pancreatic acinar cell cancers [<a href="#rid18">18</a>]) and squamous cell carcinomas, or with lymphomas and mesenchymal neoplasms. (See <a class="local">'Immunohistochemistry'</a> above.)</p><p class="headingAnchor" id="H1469012727"><span class="h2">Molecular testing</span><span class="headingEndMark"> — </span>Some molecular markers may be relevant for treatment of metastatic disease:</p><p class="bulletIndent1"><span class="glyph">●</span>Deficient DNA mismatch repair (dMMR) has been found in 5 percent of GEP NEC, and these patients should be considered candidates for therapy with an immune checkpoint inhibitor [<a href="#rid78">78</a>]. On the other hand, tumor mutational burden (TMB) is generally low in NEC and NET G3 that have proficient MMR [<a href="#rid78">78</a>]. (See  <a class="medical medical_review" href="/z/d/html/120646.html" rel="external">"Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mutations in<em> BRAF</em> are present up to 50 percent in colonic NEC [<a href="#rid78">78</a>], and <em>BRAF</em> inhibitors in combination with <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> are an option for these patients as long as they are <em>RAS</em> wild-type. (See  <a class="medical medical_review" href="/z/d/html/129349.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Approach to later lines of systemic therapy", section on 'RAS wild-type, BRAF mutated tumors'</a>.)</p><p></p><p class="headingAnchor" id="H463614774"><span class="h1">TREATMENT AND PROGNOSIS</span></p><p class="headingAnchor" id="H89618225"><span class="h2">Poorly differentiated NEC</span><span class="headingEndMark"> — </span>There is a general lack of data from prospective trials to guide clinical decision-making regarding treatment of GEP neuroendocrine carcinoma (NEC). Current treatment approaches are based primarily on retrospective reports and parallel recommendations for small cell lung cancer (SCLC). In general, many patients with GEP NEC have a poor prognosis with rapid disease progression, and there is a high proclivity for metastatic dissemination, even in the setting of clinically localized tumors. Surgery alone can be curative for localized disease, but multimodality treatment is recommended for most patients. GEP NEC are chemotherapy-responsive neoplasms, and platinum-based chemotherapy represents the backbone of treatment for both early and advanced-stage GEP NEC [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H89621926"><span class="h3">Overview of the approach to treatment</span><span class="headingEndMark"> — </span>The following represents our general approach to treatment, which is outlined in the algorithm  (<a class="graphic graphic_algorithm graphicRef132086" href="/z/d/graphic/132086.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with nonesophageal NEC who have early stage, potentially readily resectable tumors, we suggest surgical resection plus four to six cycles of adjuvant platinum-based chemotherapy (<a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a> plus <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> or <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a>). Carboplatin may be preferred for patients with contraindications to or poor tolerance of cisplatin. Chemotherapy is often given as neoadjuvant therapy. (See <a class="local">'Localized disease'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For locoregionally advanced, but nonmetastatic nonesophageal NEC (eg, T3N1 or T4), we suggest multimodality treatment that includes platinum-based chemotherapy in all cases, individualization of the use of radiation therapy depending on location and risk of locoregional recurrence, as well as surgery when feasible. Given the aggressive nature of poorly differentiated NEC, preoperative (neoadjuvant) rather than postoperative (adjuvant) treatment may be considered unless surgery can be undertaken quickly with expectation of a reasonably fast recovery. (See <a class="local">'Benefit of radiotherapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For apparently isolated locoregional esophageal primaries, chemoradiotherapy plus chemotherapy is preferred over surgery plus chemotherapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Data on extrapulmonary NEC suggest a lower frequency of central nervous metastases than has been seen with pulmonary SCLC, and we suggest not pursuing prophylactic cranial irradiation for any patient with local or locoregional disease. (See <a class="local">'Prophylactic cranial irradiation'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with metastatic NEC should be referred rapidly for palliative chemotherapy given the aggressive nature of these tumors. Standard palliative chemotherapy consists of <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> or <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> combined with <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a>; an acceptable alternative is <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> plus cisplatin. (See <a class="local">'Initial chemotherapy'</a> below.)</p><p></p><p class="bulletIndent1">The optimal duration of treatment is not established. We typically aim for at least four to six cycles of chemotherapy, but if a patient is still responding and tolerating treatment well, continuation of chemotherapy to at least maximal response is appropriate.</p><p></p><p class="headingAnchor" id="H463614782"><span class="h3">Localized disease</span><span class="headingEndMark"> — </span>A minority of patients with a GEP NEC have apparently localized disease at presentation [<a href="#rid32">32,71</a>]. Treatment recommendations for such patients are not based on prospective data, and supporting evidence from retrospective studies is quite limited. Many of these studies enrolled a heterogeneous patient population that was not exclusively GEP NEC and instead investigated outcomes for a variety of extrapulmonary NEC [<a href="#rid23">23,24,58,79,80</a>]. However, patients with localized disease, five-year survival rates can be as high as 40 to 50 percent with combined surgery and systemic therapy [<a href="#rid17">17</a>]. Nonetheless, in this context, there is consensus that local therapy alone is rarely curative and that all patients, including those with limited disease, benefit from systemic chemotherapy [<a href="#rid6">6,45,48,81-83</a>]. (See  <a class="medical medical_review" href="/z/d/html/4882.html" rel="external">"Extrapulmonary small cell cancer"</a>.)</p><p class="headingAnchor" id="H2525825402"><span class="h4">Role of surgery</span><span class="headingEndMark"> — </span>For patients with a NEC that is not in the esophagus, early stage, and potentially resectable, we suggest surgical resection in addition to systemic chemotherapy rather than chemotherapy alone. If surgery is being considered, fluorodeoxyglucose-positron emission tomography (FDG-PET) should be performed prior to resection to exclude distant metastases. (See <a class="local">'Radiographic studies'</a> above.)</p><p>For locoregional therapy of apparently localized esophageal NEC, we suggest definitive chemoradiotherapy rather than surgery.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary tumor not in the esophagus</strong> – The data supporting a benefit from resection come from retrospective reports noting that potentially curative surgery is an independent prognostic factor for better outcomes among patients undergoing multimodality therapy [<a href="#rid17">17,41,67,84-92</a>].</p><p></p><p class="bulletIndent1">As an example, in a study based on data from the National Cancer Database between 2004 and 2016, included 2314 cases with stage I to III digestive tract NEC [<a href="#rid93">93</a>]. The overall median survival was 20.7 months, and the five-year survival rate was 29.2 percent. Significant differences in survival were noted according to site and morphology. Colon NEC had the longest median survival (28.5 months with 39.7 percent five-year survival), while gallbladder and biliary NEC (median 14.8 months with 20.9 percent five-year survival) had the shortest median survival. Small cell morphology was associated with worse median survival compared with large cells and other histologies (17.7 versus 22.3 months). Even in patients undergoing chemoradiation, surgery was the only prognostic variable that significantly affected survival in stages I to II disease (HR 0.63, 95% CI 0.44-0.91) and there was also a trend towards better survival with stage III disease that was not statistically significant (HR 0.77, 95% CI 0.59-1.01).</p><p></p><p class="bulletIndent1">In general, radical surgery alone is not considered adequate therapy for G3 NEC, and the majority of patients should receive some form of adjuvant systemic therapy. (See <a class="local">'Postoperative adjuvant chemotherapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Colorectal primary</strong> – For colorectal primary tumors, the benefit of surgery may depend on cell type. In a study of 502 colorectal NEC stage I to III, three-year survival after surgery versus no surgery was 40 versus 18 percent [<a href="#rid41">41</a>] Patients with localized non-small cell CRC NEC had better survival after surgery (median 21 versus 6 months), whereas those with small cell CRC NEC did not (median survival 18 versus 14 months).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Esophageal primaries</strong> – One exception where surgery is generally not recommended, even for apparently isolated locoregional disease, is esophageal NEC, in which chemoradiotherapy plus chemotherapy is preferred over surgery plus chemotherapy. In a review of 127 patients with limited-stage small cell esophageal carcinoma, survival was superior for patients treated with radiation plus chemotherapy as compared with that for patients treated with surgery and chemotherapy (three-year overall survival 50 versus 24 percent) [<a href="#rid82">82</a>], and results seem especially poor after surgical treatment of stage III esophageal NEC [<a href="#rid82">82,86</a>].</p><p></p><p class="headingAnchor" id="H3498060630"><span class="h4">Postoperative adjuvant chemotherapy</span><span class="headingEndMark"> — </span>For most patients with apparently localized GEP NEC, we suggest adjuvant chemotherapy in conjunction with local therapy rather than local therapy alone. Following the paradigm established for limited-stage SCLC, for most patients we administer four to six cycles of platinum-based chemotherapy (<a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a> plus either <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> or <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>). This approach is consistent with current treatment guidelines from the National Comprehensive Cancer Network, the North American Neuroendocrine Tumor Society (NANETS), and the European Neuroendocrine Tumor Society [<a href="#rid81">81,83,94</a>].</p><p>There is a lack of prospective data that have established the benefit from adjuvant platinum-based chemotherapy therapy in localized GEP NEC [<a href="#rid89">89,95</a>], and recommendations have been primarily extrapolated from the treatment paradigm for limited stage SCLC, in which the contribution of chemotherapy to long-term survival in early stage disease has been demonstrated in observational studies. (See  <a class="medical medical_review" href="/z/d/html/4634.html" rel="external">"Limited-stage small cell lung cancer: Initial management", section on 'Overview of treatment and benefits'</a>.)</p><p>Retrospective reports on adjuvant chemotherapy for localized GEP NEN G3 are difficult to interpret due to a probable selection bias of which patients received adjuvant treatment. Furthermore, contemporary retrospective studies show conflicting results and suggest that the benefit of adjuvant therapy might depend, in part, on the primary site. In three reports, adjuvant chemotherapy after surgery for colorectal NEC showed a survival benefit, whereas this was not found in a fourth series of patients with gastric NEC/MiNEN [<a href="#rid96">96-99</a>]. (See <a class="local">'Pathologic diagnosis'</a> above.)</p><p>The standard regimen is <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a> plus <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> or <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a>. In our view, either carboplatin or cisplatin represents an acceptable choice. The available data in limited-stage SCLC suggest that carboplatin and cisplatin are equivalent in terms of overall survival, progression-free survival (PFS), and objective response rate, differing only in terms of toxicity [<a href="#rid100">100</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">Carboplatin</a> is more likely to be associated with grade 3 to 4 hematologic toxicities.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">Cisplatin</a> is more likely to be associated with nonhematologic toxicities, including nausea, vomiting, ototoxicity, neuropathy, and nephropathy.</p><p></p><p>Nevertheless, many clinicians, citing the curability of limited-stage SCLC and the greater experience with <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>/<a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a>, consider cisplatin/etoposide to represent the standard of care for localized disease, reserving <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> for patients with a contraindication to or intolerance of cisplatin. (See  <a class="medical medical_review" href="/z/d/html/4634.html" rel="external">"Limited-stage small cell lung cancer: Initial management", section on 'Preferred regimen: Etoposide plus cisplatin'</a>.)</p><p class="headingAnchor" id="H1182014512"><span class="h4">Benefit of radiotherapy</span><span class="headingEndMark"> — </span>For both localized and locoregionally advanced esophageal GEP NEC, we suggest chemoradiotherapy plus chemotherapy rather than surgery followed by chemotherapy. (See <a class="local">'Role of surgery'</a> above.)</p><p>For locoregionally advanced nonmetastatic nonesophageal NEC (ie, T3N1 or T4, (see <a class="local">'Staging system'</a> above)), we suggest a multimodality approach that includes chemotherapy in all cases, individualization of the use of radiation therapy depending on location (eg, anorectum) and risk of locoregional recurrence, as well as surgery when feasible. Given the aggressive nature of NEC, we often use neoadjuvant rather than adjuvant RT; however, many cases of NEC are diagnosed after surgery. (See <a class="local">'Integration of local therapy'</a> below.)</p><p>The use of chemoradiotherapy for locally or locoregionally advanced NEC (T3 to T4 and/or lymph node involvement) using a platinum agent plus <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a> is based upon the treatment paradigm for limited-stage SCLC, in which the addition of thoracic radiation therapy to systemic chemotherapy results in a small, statistically significant improvement in survival compared with the use of chemotherapy alone, albeit with an increase in toxicity. (See  <a class="medical medical_review" href="/z/d/html/4634.html" rel="external">"Limited-stage small cell lung cancer: Initial management", section on 'Benefit of RT'</a>.)</p><p class="headingAnchor" id="H346513529"><span class="h4">Integration of local therapy</span><span class="headingEndMark"> — </span>There are no prospective trials addressing how best to integrate local and systemic therapy into the treatment of localized or locoregional GEP NEC. We mainly agree with consensus-based guidelines from NANETS, which suggest the following approach [<a href="#rid81">81</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Surgery followed by adjuvant chemotherapy (four to six cycles of a platinum agent with <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a>) for most early stage tumors (T1 to T2, N0). (See <a class="local">'Staging system'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adjuvant or neoadjuvant chemoradiation is reasonable if the risk of local recurrence is thought to be higher than average, depending upon the anatomic location of the tumor (eg, anorectum). However, distant recurrences are far more frequent than local recurrences, and these patients all need four to six cycles of systemic platinum-based chemotherapy as well.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chemoradiotherapy is also a reasonable option for locally or locoregionally advanced disease (T3 to T4 and/or lymph node involvement), using concurrent radiation therapy plus a platinum agent with <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a>. This treatment can be considered definitive or neoadjuvant, depending on whether surgical resection is feasible. All patients should receive four to six cycles of platinum-based chemotherapy in addition to chemoradiotherapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A neoadjuvant approach to treatment with chemotherapy alone followed by surgery is an option for patients with localized nonesophageal tumors, especially if it is estimated that postoperative morbidity will be high and adjuvant treatment might be delayed.</p><p></p><p class="headingAnchor" id="H346511849"><span class="h4">Prophylactic cranial irradiation</span><span class="headingEndMark"> — </span>Data on extrapulmonary poorly differentiated NEC suggest a lower frequency of central nervous metastases than seen with pulmonary SCLC, and we do not suggest prophylactic cranial irradiation for these patients in the absence of demonstrable brain metastases. (See <a class="local">'Clinical presentation'</a> above and  <a class="medical medical_review" href="/z/d/html/4631.html" rel="external">"Prophylactic cranial irradiation for patients with small cell lung cancer"</a>.)</p><p class="headingAnchor" id="H463615605"><span class="h3">Metastatic disease</span><span class="headingEndMark"> — </span>Systemic chemotherapy is the mainstay of care for individuals with metastatic NEC. Systemic chemotherapy is palliative, but can improve survival. In a retrospective review of 305 patients with advanced (301 metastatic) GEP NEC diagnosed at 12 Nordic hospitals during 2000 to 2009, median survival for those who received palliative chemotherapy was 11 months; for the 53 who did not receive chemotherapy, it was one month [<a href="#rid35">35</a>]. These data reflect, in part, worse baseline health in the group receiving best supportive care.</p><p class="headingAnchor" id="H3435304000"><span class="h4">General approach</span><span class="headingEndMark"> — </span>Our general approach to treatment of metastatic GEP NEC is as follows, as outlined in the algorithm  (<a class="graphic graphic_algorithm graphicRef132086" href="/z/d/graphic/132086.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Rapid referral for palliative chemotherapy is necessary given the aggressive nature of these tumors. For most patients, standard palliative chemotherapy consists of <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> or <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> combined with <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a>; an acceptable alternative is <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> plus cisplatin, but we generally prefer carboplatin or cisplatin plus etoposide. (See <a class="local">'Initial chemotherapy'</a> below.)</p><p></p><p class="bulletIndent1">The optimal duration of treatment is not established. We typically aim for four to six cycles of therapy, but if a patient is still responding and tolerating treatment well, continuation of chemotherapy to at least maximal response is appropriate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Surgical metastasectomy is generally not recommended in the management of GEP NEC. However, selected patients may benefit from liver surgery; decision-making must be individualized. (See <a class="local">'Role of metastasectomy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with platinum-sensitive disease may benefit from retreatment with <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> or <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> plus <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a> if relapse occurs at least three to six months after discontinuation of first-line treatment. While second-line regimens have not been evaluated rigorously, options include temozolomide-, fluoropyrimidine-, irinotecan-, and oxaliplatin-based regimens. (See <a class="local">'Second-line chemotherapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Given limited treatment options in the platinum-refractory setting and the potential for sustained remission with immunotherapy, combination immunotherapy, particularly with <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a> and <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> is a reasonable option for GEP NEC for second-line treatment and beyond.</p><p></p><p class="headingAnchor" id="H89618368"><span class="h4">Initial chemotherapy</span><span class="headingEndMark"> — </span>We suggest treatment of metastatic GEP NEC with a two-drug platinum-based regimen, generally <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> or <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> plus <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a>. This approach is consistent with all published guidelines for this disease [<a href="#rid53">53,81,83,94,101,102</a>]. An acceptable alternative is <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> plus cisplatin, although we generally prefer a platinum plus etoposide regimen. (See  <a class="medical medical_review" href="/z/d/html/4633.html" rel="external">"Extensive-stage small cell lung cancer: Initial management", section on 'Rationale for platinum-etoposide as choice of chemotherapy'</a>.)</p><p>Most cases of metastatic GEP NEC are responsive to systemic platinum-based chemotherapy, but almost all patients eventually relapse and die of their disease. However, for the subgroup of colorectal primary NEC, results after platinum plus <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a> are poor with an immediate disease progression in 60 percent of cases [<a href="#rid35">35</a>].</p><p>The available data on outcomes from palliative chemotherapy come from retrospective data primarily including patients with metastatic disease. Most of the available data are with <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> or <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> plus <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a>; there are few comparative studies with other regimens.</p><p class="headingAnchor" id="H150854714"><span class="h5">Platinum plus etoposide</span><span class="headingEndMark"> — </span>The benefits of platinum plus <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a> chemotherapy in metastatic GEP NEC can be illustrated by the following retrospective reports:</p><p class="bulletIndent1"><span class="glyph">●</span>In a large Nordic consortium retrospective study, <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> or <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> plus <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a> was prescribed for 252 patients with advanced GEP NEC [<a href="#rid35">35</a>].<sup> </sup>The response rate was 31 percent, PFS was four months, and median survival was 11 months. No significant differences in outcomes were observed in patients treated with cisplatin versus carboplatin. A Ki-67 threshold of 55 percent was predictive of response to chemotherapy: tumors with Ki-67 &lt;55 percent were much less responsive to platinum-based chemotherapy (response rate 15 versus 42 percent) but had a significantly longer survival (median overall survival 14 versus 10 months) compared with patients with higher Ki-67 levels  (<a class="graphic graphic_figure graphicRef98816" href="/z/d/graphic/98816.html" rel="external">figure 3</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a series of 123 evaluable patients who received a platinum plus <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a> regimen for first-line treatment of metastatic NEC, 61 had an objective response (50 percent) and 29 others (23 percent) achieved stable disease as the best response [<a href="#rid32">32</a>]. Median PFS was 6.2 months and median overall survival was 11.6 months.</p><p></p><p>The optimal duration of treatment is not established. We typically aim for four to six cycles of therapy, but if a patient is still responding and tolerating treatment well, continuation of chemotherapy to at least maximal response is appropriate.</p><p class="headingAnchor" id="H1042949419"><span class="h5">Is there benefit from adding an immune checkpoint inhibitor?</span><span class="headingEndMark"> — </span>The addition of an immune checkpoint inhibitor targeting PD-1 or PD-L1 (eg, <a class="drug drug_general" data-topicid="108314" href="/z/d/drug information/108314.html" rel="external">atezolizumab</a>, <a class="drug drug_general" data-topicid="112994" href="/z/d/drug information/112994.html" rel="external">durvalumab</a>) to first-line chemotherapy has become a standard of care in SCLC based on phase III studies. Whether this strategy is appropriate for extrapulmonary NEC is not yet known and is the subject of a <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT05058651%3Fterm%3DSWOG%2B2012%26cond%3Dpoorly%2Bdifferentiated%2Bextrapulmonary%2Bneuroendocrine%2Bcarcinoma%26draw%3D2%26rank%3D1&amp;token=NAdEs%2FdiV29EwHyUsc6bQn2ssTP4xE%2FAV7StrtkEGzBhc%2Frl8CgcCET%2BlxTTobapYxXiE2VgIo3V5OrzS9wfWXNSW8e%2BkmA3uxDVOegjnWF0Zq3uqBWAOeIjwDDEwXhN%2FjsezFF%2F7E2kXwX1XstKiE2dD58Z5autndluUIO4IhPRjuhB4wj5iLSr7v5R0Vwh&amp;TOPIC_ID=98796" target="_blank">randomized phase II/III study sponsored by SWOG</a>. Until information from that study is available, we suggest not pursuing this approach. (See  <a class="medical medical_review" href="/z/d/html/4633.html" rel="external">"Extensive-stage small cell lung cancer: Initial management", section on 'Preferred option: Immunotherapy plus platinum-etoposide'</a>.)</p><p class="headingAnchor" id="H89621737"><span class="h5">Irinotecan-based regimens</span><span class="headingEndMark"> — </span>We consider an <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> plus <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> doublet to be an acceptable alternative initial chemotherapy regimen in patients with metastatic GEP NEC, although for most patients we prefer <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> or cisplatin plus <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a>.</p><p>At least two studies have directly compared <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a>/<a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> versus etoposide/cisplatin, both of which concluded that neither regimen was superior [<a href="#rid103">103,104</a>]. In the randomized JCOG-1213 trial, which directly compared both regimens in 170 patients with chemotherapy-naïve recurrent or unresectable NEC arising from the gastrointestinal or hepatobiliary tract [<a href="#rid104">104</a>]. Median survival was not significantly better with etoposide/cisplatin (median 12.5 versus 10.9 months, HR 1.04, 95% CI 0.79-1.37), and PFS and objective response rates were similar. Grade 3 or 4 adverse events were more common with etoposide/cisplatin, especially neutropenia.</p><p class="headingAnchor" id="H3041156598"><span class="h4">Role of metastasectomy</span><span class="headingEndMark"> — </span>Surgical metastasectomy is generally not recommended in the management of GEP NEC [<a href="#rid6">6</a>]. However, selected patients may benefit from liver surgery [<a href="#rid84">84,105</a>]. In a Nordic registry, 32 cases of 840 (3.8 percent) GEP NEC patients had hepatic metastasectomy, with a five-year survival of 43 percent [<a href="#rid105">105</a>]. Factors for improved survival was Ki-67 &lt;55 percent and receiving adjuvant chemotherapy. The decision to pursue surgery must be individualized.</p><p class="headingAnchor" id="H89620011"><span class="h4">Second-line chemotherapy</span><span class="headingEndMark"> — </span>There are few data on second-line therapy (and no studies comparing chemotherapy with best supportive care), and a standard regimen has not been established. Patients who progress more than three months after discontinuation of first-line treatment may still be platinum sensitive. In the Nordic NEC study described above, retreatment with the same platinum-based regimen yielded a response rate of 15 percent, with another 27 percent achieving stable disease [<a href="#rid35">35</a>].</p><p>No standard cytotoxic chemotherapy regimen has been established beyond first-line treatment in platinum-refractory cases; however, several retrospective studies suggest that GEP NEC patients can benefit from further lines of chemotherapy after failure of platinum plus <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a> treatment [<a href="#rid35">35,45,106-109</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Temozolomide</strong><strong>-based chemotherapy</strong> – <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">Temozolomide</a> is commonly used in the second-line setting [<a href="#rid45">45,106,107,110</a>]. As an example, temozolomide was given with or without <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a> and <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> as second-line treatment after cisplatin-based chemotherapy in a cohort of 25 patients with GEP NEC [<a href="#rid106">106</a>].<sup> </sup>The response rate was 33 percent, another nine patients had stable disease, and median overall survival was 22 months from time of diagnosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Irinotecan</strong><strong>-based regimens</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>FOLFIRI</strong> – FOLFIRI is an option for patients with platinum-refractory NEC [<a href="#rid111">111</a>]. In a series of 19 platinum-resistant NEC patients treated with <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> plus short-term infusional <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> plus <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> (FOLFIRI), the response rate was 31 percent and median PFS was four months [<a href="#rid112">112</a>]. In a second report of 72 patients receiving second- or third-or-more-line FOLFIRI after failing an initial platinum plus <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a> regimen (54 evaluable patients), there were 13 objective responders (24 percent) and the median PFS was 2.9 months [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Liposomal </strong><strong>irinotecan</strong><strong> plus FU</strong> – A multicenter randomized phase II trial of 58 patients with poorly differentiated extrapulmonary NEC (69 percent GEP) who had prior cisplatin-based chemotherapy directly compared second-line <a class="drug drug_general" data-topicid="104962" href="/z/d/drug information/104962.html" rel="external">liposomal irinotecan</a> (70 mg/m<sup>2</sup> as free base) in combination with short-term infusional FU (2400 mg/m<sup>2</sup> plus <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a>) every 14 days versus <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> monotherapy (75 mg/m<sup>2</sup> every 21 days) [<a href="#rid113">113</a>]. In a preliminary report presented at the 2022 annual ASCO meeting, response rates were similar (10.3 percent) and PFS was three versus two months and the six-month overall PFS rate (the primary endpoint) favored liposomal irinotecan (32 versus 15 percent) as did median overall survival (nine versus five months), with manageable toxicity. In our view, these results are premature, and cannot yet be used to inform clinical practice.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oxaliplatin</strong><strong>-based chemotherapy</strong> – In a report of 17 evaluable patients with NEC (12 GEP) receiving <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a> plus short-term infusional <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> plus <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> (FOLFOX) after progression on <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> or <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a>, five had a partial response (29 percent), while six others (33 percent) had stable disease [<a href="#rid109">109</a>]. PFS and overall survival were superior for patients with a Ki-67 &lt;55 versus &gt;55 percent (median PFS 6.2 versus 3.6 months and median overall survival 19.5 versus 8.5 months). In another series of 33 patients receiving second- or third-or-more-line FOLFOX after failing an initial platinum plus <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a> regimen (24 evaluable patients), there were four objective responders (16 percent) and the median PFS was 2.3 months [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent1">Very limited experience with a combination regimen that includes <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a>, <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a>, and short-term infusional <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> plus <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> (modified FOLFIRINOX) suggests some efficacy in pancreatic NEC [<a href="#rid114">114</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topotecan</strong><strong>-based chemotherapy</strong> – <a class="drug drug_general" data-topicid="10007" href="/z/d/drug information/10007.html" rel="external">Topotecan</a> is recommended in several guidelines extrapolating from data from studies of recurrent SCLC. (See  <a class="medical medical_review" href="/z/d/html/4614.html" rel="external">"Treatment of refractory and relapsed small cell lung cancer", section on 'Topotecan'</a>.)</p><p></p><p class="bulletIndent1">Few data are available in GEP NEC. In a small retrospective study in which <a class="drug drug_general" data-topicid="10007" href="/z/d/drug information/10007.html" rel="external">topotecan</a> was given as second- to fourth-line treatment in 22 GEP NEC patients, the response rate was poor: 77 percent had immediate disease progression, 23 percent had stable disease, and median survival was only 3.2 months [<a href="#rid115">115</a>].</p><p></p><p class="headingAnchor" id="H1736735451"><span class="h4">Immunotherapy</span><span class="headingEndMark"> — </span>Immune checkpoint inhibitor immunotherapy that targets both programmed cell death-1 (PD-1) and cytotoxic T lymphocyte associated antigen 4 checkpoints is a reasonable alternative to cytotoxic chemotherapy for second-line treatment and beyond in patients with platinum-refractory disease, although data are limited. Response rates are fairly low, but some patients can achieve long-term remission. Patients whose tumors have deficient mismatch repair (dMMR)/high levels of microsatellite instability (MSI-H) or high levels of tumor mutational burden (TMB; 10 to 15 mutations/megabase) are much more likely to benefit from immunotherapy. (See  <a class="medical medical_review" href="/z/d/html/120646.html" rel="external">"Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors"</a>.)</p><p>Studies evaluating single-agent therapy with an immune checkpoint inhibitor targeting PD-1 have shown very low response rates [<a href="#rid116">116-119</a>]; however, trials of combined targeting of both PD-1 plus CTLA-4 have been more promising, with some patients achieving long-term disease control. Most of the data are in combined populations of NEC/NET G3:</p><p class="bulletIndent1"><span class="glyph">●</span>A prospective study of <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a> in 19 patients with G3 NEN (median Ki-67 80 percent) reported an objective response rate of 26 percent and PFS two months [<a href="#rid120">120</a>]. One-third of patients were still progression-free at six months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective evaluation of 34 patients with G3 NEN (79 percent NEC, 21 GEP) treated with <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> and <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a> reported an objective response rate of 15 percent with PFS of only one month [<a href="#rid121">121</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A preliminary report of a prospective study of <a class="drug drug_general" data-topicid="112994" href="/z/d/drug information/112994.html" rel="external">durvalumab</a> plus <a class="drug drug_general" data-topicid="139983" href="/z/d/drug information/139983.html" rel="external">tremelimumab</a> in G3 NEN reported a response rate of 9 percent and 9 month survival was 36 percent among GEP NEN G3 patients [<a href="#rid122">122,123</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The NICENEC single-arm phase II trial studied first-line treatment with <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> combined with up to six cycles of <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> and <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a> followed by maintenance nivolumab in 38 patients with NEN G3 of GEP (82 percent) or unknown (18 percent) origin; 53 percent were poorly differentiated (NEC) [<a href="#rid124">124</a>]. Response rate was 50 percent, PFS was 5.7 months and 39 percent of patients were free of progression after six months. Understanding the true benefit of adding an immune checkpoint inhibitor to first-line chemotherapy compared with chemotherapy alone will require a randomized trial.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Preliminary results are also available from the randomized phase II NIPINEC trial, in which 185 patients (93 GEP NEC, 92 lung NEC) with platinum-refractory disease were randomized between <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> alone or with <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a> [<a href="#rid125">125</a>]. The primary endpoint was objective response rate at eight weeks, which was achieved by a higher fraction with combined treatment (14.9 versus 7.2 percent); however, this did not translate into better median PFS (1.8 versus 1.9 months) or overall survival (7.2 versus 5.8 months).</p><p></p><p>Deficient mismatch repair (dMMR), the biologic footprint of which is MSI-H, is present in about 5 percent of GEP NEC cases, most frequently in colorectal primaries [<a href="#rid29">29,126</a>]. As dMMR/MSI-H seems to be an agnostic tumor marker for the benefit of checkpoint inhibitors, routine MSI or MMR testing is important for NEC, particularly of colorectal origin. Patients whose tumors have dMMR/MSI-H or high levels of TMB (&gt;10/15 per megabase (see <a class="local">'Immunotherapy'</a> below)) are much more likely to benefit from early-line immunotherapy treatment using single-agent <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>. (See  <a class="medical medical_review" href="/z/d/html/120646.html" rel="external">"Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors"</a>.)</p><p>The role of first-line immunotherapy in unselected GEP NEC patients is uncertain. While addition of <a class="drug drug_general" data-topicid="108314" href="/z/d/drug information/108314.html" rel="external">atezolizumab</a> or <a class="drug drug_general" data-topicid="112994" href="/z/d/drug information/112994.html" rel="external">durvalumab</a> to platinum plus <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a> has been shown to modestly improve survival in patients with extensive stage SCLC unselected for PD-L1 overexpression, dMMR or high TMB, and this is now a standard approach to initial therapy, such data does not exist in GEP NEC. (See  <a class="medical medical_review" href="/z/d/html/4633.html" rel="external">"Extensive-stage small cell lung cancer: Initial management", section on 'Rationale for addition of immune checkpoint inhibitors to chemotherapy'</a>.)</p><p>Given limited treatment options in the platinum-refractory setting and the potential for sustained remission with immunotherapy, the above results suggest that combination immunotherapy, particularly with <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a> plus <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a>, is an option for GEP NEC for second-line therapy and beyond. However, it should be noted that interpretation of available data is often challenging, due to inclusion of multiple primary sites (including lung), frequent lack of information about dMMR status and TMB, and lack of detail about the type of G3 GEP NEN enrolled (well differentiated or poorly differentiated). For NET G3, we would generally reserve immunotherapy for patients who are refractory to several lines of systemic therapy. (See <a class="local">'Immunotherapy'</a> below.)</p><p class="headingAnchor" id="H3299168306"><span class="h4">Other molecularly targeted treatments</span><span class="headingEndMark"> — </span>Colorectal NEC frequently (up to 40 percent) has a <em>BRAF</em> mutation [<a href="#rid122">122</a>]. A combination of BRAF-inhibitor/EGFR-inhibitor/MEK-inhibitor has shown benefit in metastatic colorectal <em>RAS</em> wild-type but <em>BRAF</em>-mutant adenocarcinomas and in case reports of colorectal NEC [<a href="#rid127">127</a>]. <a class="drug drug_general" data-topicid="118325" href="/z/d/drug information/118325.html" rel="external">Encorafenib</a> with <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> has been approved for second-line treatment of <em>BRAF</em> V600e mutated metastatic colorectal cancer, and not limited to adenocarcinoma cases. We would consider the doublet regimen of cetuximab and encorafenib in <em>BRAF</em> v600e mutated NEC patients with platinum-refractory disease based upon the colorectal adenocarcinoma data. (See  <a class="medical medical_review" href="/z/d/html/129349.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Approach to later lines of systemic therapy", section on 'RAS wild-type, BRAF mutated tumors'</a>.)</p><p class="headingAnchor" id="H4283277365"><span class="h3">Prognosis</span><span class="headingEndMark"> — </span>Prognosis for GEP NEC is poor for all stages of disease [<a href="#rid6">6,17,18,21,35,56,128</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Within several retrospective series, median survival was approximately 38 months for localized disease, 16 months for regional disease, and 5 to 14 months for metastatic disease from the time of diagnosis [<a href="#rid32">32,35,56</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similarly, in an analysis of data derived from the Surveillance, Epidemiology, and End Results database of the National Cancer Institute, the median survival for GEP NEC was 33.9 months with localized disease, 16.3 months with regional disease, and 5.2 months with distant disease [<a href="#rid17">17</a>]. Corresponding five-year survival rates were 42, 25.6, and 4.7 percent, and varied depending on primary tumor site and morphology (eg, better for large cell than small cell GEP NEN G3).</p><p></p><p>Long-term relapse-free survival is possible among patients with localized disease who are treated with multimodality therapy. In one large series of patients with stage I, II, or III GEP NEC derived from the National Cancer Database, five-year survival was approximately 30 percent, and was best in those with colonic primaries (five-year survival 40 percent) [<a href="#rid93">93</a>] Regardless of primary site, survival was better when surgery was a component of therapy as compared with nonsurgical management. (See <a class="local">'Localized disease'</a> above.)</p><p>Prognosis is worse for advanced disease:</p><p class="bulletIndent1"><span class="glyph">●</span>The Nordic NEC study retrospectively compared 252 patients with advanced GEP NEC treated with chemotherapy with 53 patients treated with best supportive care and found that overall survival was 11 months in the chemotherapy group and 1 month in the best supportive care group. These data reflect in part, however, worse baseline health in the group receiving best supportive care [<a href="#rid35">35</a>]. Two-year survival was 14 percent and three-year survival was 9.5 percent in the cohort receiving chemotherapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prognosis is especially poor for a large bowel primary site with advanced disease. Even with aggressive therapy that includes platinum-based systemic chemotherapy, there are only rare reports of long-term survivors [<a href="#rid41">41,128-132</a>]. In one review of 47 cases, the median survival was six months and only 15 percent were still alive at one year [<a href="#rid130">130</a>].</p><p></p><p>Baseline factors related to shorter survival in patients receiving chemotherapy include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Poor performance status  (<a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">table 3</a>) (performance status of 0, 1, and 2 corresponded with overall survival of 18, 12, and 5 months, respectively) [<a href="#rid32">32,35,50,133</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Higher proliferation rate [<a href="#rid8">8,35,107,109,134</a>]. In the Nordic NEC study, Ki-67 rate &gt;55 percent was associated with a significantly worse overall survival of 10 versus 14 months  (<a class="graphic graphic_figure graphicRef98816" href="/z/d/graphic/98816.html" rel="external">figure 3</a>) [<a href="#rid35">35</a>]. However, this association has not been seen in other series [<a href="#rid32">32</a>], while others have used a higher Ki-67 cutoff (&gt;80 percent) in prognostic modeling [<a href="#rid133">133</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Elevated lactate dehydrogenase and other tumor markers [<a href="#rid32">32,35,50</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thrombocytosis [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Primary tumor in the esophagus or large bowel compared with stomach and pancreas [<a href="#rid35">35,50,135</a>].</p><p></p><p class="headingAnchor" id="H441838886"><span class="h2">High-grade, well-differentiated tumors (NET G3)</span><span class="headingEndMark"> — </span>A minority of GEP NEN G3, particularly those of pancreatic origin, have a Ki-67 index &gt;20 percent but well-differentiated histology (neuroendocrine tumor [NET] G3). (See <a class="local">'High-grade well-differentiated tumors'</a> above.)</p><p class="headingAnchor" id="H3650380041"><span class="h3">Overview of the approach to treatment</span><span class="headingEndMark"> — </span>The best way to treat these patients is not established, and there are few data to support a specific strategy; our approach is outlined in the algorithm  (<a class="graphic graphic_algorithm graphicRef132086" href="/z/d/graphic/132086.html" rel="external">algorithm 1</a>), and described in more detail below:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with apparently localized potentially resectable disease, we suggest resection rather than nonoperative therapy. (See <a class="local">'Localized disease'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with advanced NET G3 often respond relatively poorly to platinum plus <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a> regimens, and platinum-based chemotherapy may not be the most appropriate first-line treatment. Eligible patients should be encouraged to enroll in therapeutic trials testing the benefits of specific regimens. Off protocol, regimens used in NET G2 (eg, temozolomide-based chemotherapy, <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a>, and <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> [<a href="#rid136">136,137</a>]) are all reasonable options. We generally prefer first-line temozolomide-based chemotherapy, but FOLFOX is another option [<a href="#rid32">32,109,138,139</a>]. We do not generally treat NET G3 patients with platinum-based first-line chemotherapy, unless the disease is exceptionally aggressive at outset. Platinum-based chemotherapy is a reasonable second-line approach at the time of disease progression. Another option for salvage therapy is immunotherapy with <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a> plus <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a>; however, we would generally recommend this in unselected patients only after progression on several lines of treatment. (See <a class="local">'Advanced disease'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Peptide receptor radioligand therapy (PRRT) using radiolabeled somatostatin analogs is also a reasonable option for GEP NET G3 with a high uptake on somatostatin receptor imaging. (See  <a class="medical medical_review" href="/z/d/html/16901.html" rel="external">"Metastatic well-differentiated gastrointestinal neuroendocrine (carcinoid) tumors: Systemic therapy options to control tumor growth", section on 'Radiolabeled somatostatin analogs'</a> and  <a class="medical medical_review" href="/z/d/html/90664.html" rel="external">"Metastatic well-differentiated pancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion", section on 'Radiolabeled somatostatin analogs'</a>.)</p><p></p><p class="headingAnchor" id="H2400314657"><span class="h3">Localized disease</span><span class="headingEndMark"> — </span>Although definitive data are scarce, surgery is appropriate for NET G3 patients with localized and locoregional disease, as it is for low (G1)- and intermediate-grade (G2) NET [<a href="#rid84">84,85,140,141</a>] (see <a class="local">'Role of surgery'</a> above). The role of adjuvant chemotherapy is unknown, and we do not suggest it for most patients [<a href="#rid83">83</a>].</p><p class="headingAnchor" id="H2022036540"><span class="h3">Advanced disease</span><span class="headingEndMark"> — </span>The most appropriate approach for patients with advanced NET G3 has not been established and requires clinical judgment that takes into account factors such as proliferative rate, disease burden, tumor location, pace of disease progression, and the results of somatostatin receptor imaging.</p><p class="headingAnchor" id="H1789307292"><span class="h4">Role of liver-directed therapy</span><span class="headingEndMark"> — </span>The role of liver-directed therapy for hepatic-predominant metastatic NET G3 is uncertain, as the available data are very limited. However, as with NET G2, some patients with limited, liver-isolated metastases may be appropriate candidates for hepatic metastasectomy or other nonsurgical liver-directed therapies. (See  <a class="medical medical_review" href="/z/d/html/16105.html" rel="external">"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion", section on 'Hepatic-predominant metastatic disease'</a>.)</p><p class="headingAnchor" id="H4259152330"><span class="h4">Chemotherapy</span><span class="headingEndMark"> — </span>We suggest temozolomide-based chemotherapy for most patients, FOLFOX is another option. Despite the general paucity of data, we do not generally treat NET G3 patients with platinum-based first-line chemotherapy, unless the disease is exceptionally aggressive at outset.</p><p>In contrast to GEP NEC, multiple studies suggest relatively low response rates to platinum plus <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a> regimens in this population [<a href="#rid7">7,11,28,34,35</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a large retrospective study of 252 GEP NEN of all types, response rates to platinum plus <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a> were 42 percent in tumors with a Ki-67 index &gt;55 percent versus 15 percent in tumors with a Ki-67 index &lt;55 percent [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a series of 30 patients with NET G3 seen in a single institution over a 27-year period of time complete or partial responses to a cisplatin-based regimen were seen in two of eight cases (25 percent), and median PFS was only three months [<a href="#rid138">138</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a second report of 125 patients with GEP NEN G3 treated with a platinum plus <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a> first-line chemotherapy regimen, the objective response rate for the 113 poorly differentiated NEC was higher than it was for the 12 NET G3 (35 versus 17 percent), as was the overall disease control rate (68 versus 33 percent), but the median overall survival was not reached in those with a NET G3, compared with 16.4 months with NEC [<a href="#rid11">11</a>].</p><p></p><p>However, the optimal treatment for patients with NET G3 is not established, since this population has been excluded from most prospective studies. Most retrospective series of platinum-based chemotherapy for NEN G3 are a mixture of NET G3 and NEC, and specific data on responses and outcomes for the NET G3 subgroup are scarce and based on a very small number of patients. Nevertheless, despite the general paucity of data, we do not generally treat NET G3 patients with platinum-based first-line chemotherapy, unless the disease is exceptionally aggressive at outset.</p><p>Temozolomide-based chemotherapy (eg, <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> plus <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a>) is active in NET G3 [<a href="#rid137">137,138</a>]. Oxaliplatin-based regimens (eg, FOLFOX) are also active [<a href="#rid32">32,109,138</a>]. There are no comparator trials.</p><p>Additional information on chemotherapy responsiveness is expected from an ongoing randomized trial (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02595424&amp;token=nbsXe3i4qfUea5RCPRHtOS7yhoEzH%2BMCpwZ1%2F1ekxPMaXEoEICUeOgnKDxcVsxCBb1SyJwKcRK%2F6O9OkAIVTAA%3D%3D&amp;TOPIC_ID=98796" target="_blank">ECOG-ACRIN EA2142</a>) comparing initial <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a> plus <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> with <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> plus <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a> in patients with GEP NEN G3, including those with GEP NET G3.</p><p class="headingAnchor" id="H4146759517"><span class="h4">Somatostatin analogs and other targeted therapy</span><span class="headingEndMark"> — </span>Some of these patients may benefit from other treatments used for GEP NET G2, including molecularly targeted therapy (eg, <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> [<a href="#rid134">134</a>]), and somatostatin analogs (conventional or radiolabeled) if the tumor expresses somatostatin receptors (see <a class="local">'Peptide receptor radioligand therapy'</a> below). For patients with positive somatostatin receptor imaging and favorable tumor biology, a somatostatin analog could be considered, although data are lacking.</p><p class="headingAnchor" id="H813988332"><span class="h4">Peptide receptor radioligand therapy</span><span class="headingEndMark"> — </span>PRRT using radiolabeled somatostatin analogs is a reasonable option for GEP NET G3 with a high uptake at all disease sites on somatostatin receptor imaging.</p><p>PRRT using radiolabeled somatostatin analogs is regularly used for low- or intermediate-grade NET with a high uptake on somatostatin receptor imaging. (See  <a class="medical medical_review" href="/z/d/html/16901.html" rel="external">"Metastatic well-differentiated gastrointestinal neuroendocrine (carcinoid) tumors: Systemic therapy options to control tumor growth", section on 'Somatostatin receptor-expressing tumors'</a> and  <a class="medical medical_review" href="/z/d/html/90664.html" rel="external">"Metastatic well-differentiated pancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion", section on 'Peptide receptor radioligand therapy'</a>.)</p><p>There are evolving data on the efficacy of PRRT in high-grade NEN [<a href="#rid70">70,142-145</a>]. In the largest report, a retrospective cohort study at 12 centers in 149 patients with somatostatin receptor-expressing GEP NEN G3 (n = 89 for pancreatic primary tumor, n = 34 for GI primary tumor, n = 26 for unknown primary tumor, n = 60 for well differentiated, n = 62 for poorly differentiated, n = 9 for intermediate grade, n = 18 for grade not specified), PRRT was administered as first-line (n = 30), second-line (n = 62), or later-line treatment (n = 57) [<a href="#rid143">143</a>]. Of the 114 evaluable patients, 1 percent had a complete response, 41 percent had a partial response, 38 percent had stable disease, and 20 percent had progressive disease as the best response. In the entire cohort, median PFS was 14 months and overall survival was 29 months. Outcomes were better among those with lower proliferative levels (for Ki-67 21 to 54 versus ≥55 percent: PFS 16 versus 6 months and overall survival 31 versus 9 months). Outcomes were also better for those with well-differentiated (n = 60) as compared with poorly differentiated NEN (n = 62): PFS 19 versus 8 months (p &lt;0.001) and overall survival 44 versus 19 months (p &lt;0.001). Grade 3 or 4 hematologic or renal toxicity occurred in 17 percent of patients.</p><p>Notably, patients with GEP NEN G3 who have a discordant uptake pattern on PET imaging (ie, FDG-PET positive lesions without uptake on somatostatin receptor imaging) do not seem to benefit from PRRT [<a href="#rid70">70</a>].</p><p class="headingAnchor" id="H553743370"><span class="h4">Immunotherapy</span><span class="headingEndMark"> — </span>Immune checkpoint inhibitor immunotherapy with combined <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a> plus <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> is also a reasonable option for later lines of systemic therapy. Although response rates are fairly low, some patients can achieve long-term remission. As noted above, most of the data are in combined populations with GEP NEC/NET G3. (See <a class="local">'Immunotherapy'</a> above.)</p><p class="headingAnchor" id="H463616989"><span class="h3">Prognosis</span><span class="headingEndMark"> — </span>Survival of patients with GEP NET G3 is significantly better than that of patients with GEP NEC [<a href="#rid7">7,11,18,34,57,71</a>]. In one report of 166 patients with metastatic, thoracic or GEP NEN, median survival for patients with GEP NET G3 was 41 months, compared with 17 months for non-small cell GEP NEC [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H3144227988"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111962.html" rel="external">"Society guideline links: Well-differentiated gastroenteropancreatic neuroendocrine tumors"</a>.)</p><p class="headingAnchor" id="H463615308"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition, presentation, diagnosis, and staging</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>High-grade (grade 3 [G3]) gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) are heterogeneous group. Most are poorly differentiated neuroendocrine carcinomas ([NEC] G3), with a propensity for distant metastases and an ominous prognosis, even when localized. A subset are G3 but well differentiated (neuroendocrine tumor [NET] G3), with a prognosis that is better than NEC G3 but worse than well-differentiated intermediate-grade (grade 2 [G2]) NET  (<a class="graphic graphic_table graphicRef122325" href="/z/d/graphic/122325.html" rel="external">table 1</a>). (See <a class="local">'Classification and biologic behavior'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The most common primary tumor locations for a NEC are the esophagus, stomach, pancreas, and large bowel, whereas NET G3 are mainly located in the pancreas. Presenting symptoms may be generalized or site specific. A clinical presentation due to secretion of specific peptide hormones or bioamines is extremely uncommon. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The diagnosis requires histologic examination of tumor morphology, immunohistochemical staining for markers of neuroendocrine differentiation, and determination of the proliferative rate with Ki-67 staining or mitotic index. (See <a class="local">'Pathologic diagnosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Staging evaluation includes cross-sectional imaging of the chest, abdomen, and pelvis, and, in some cases, fluorodeoxyglucose-positron emission tomography (FDG-PET). Somatostatin receptor-based imaging, is reasonable for NET G3 or in cases where differentiation is uncertain. (See <a class="local">'Radiographic studies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of local and locoregional NEC</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For all patients with a NEC, we suggest platinum-containing chemotherapy in conjunction with locoregional therapy rather than locoregional therapy alone (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Often, chemotherapy is administered in the neoadjuvant setting prior to locoregional therapy. (See <a class="local">'Postoperative adjuvant chemotherapy'</a> above.)</p><p></p><p class="bulletIndent2">The standard regimen is four to six cycles of <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a> plus either <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> or <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a>. Carboplatin may be preferred for patients with contraindications to or poor tolerance of cisplatin. (See <a class="local">'Localized disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Recommendations for locoregional therapy depend on tumor location:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with a localized potentially resectable NEC that is not in the esophagus, we suggest surgical resection plus platinum-based chemotherapy rather than chemotherapy alone (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We perform FDG-PET prior to resection to exclude distant metastases. (See <a class="local">'Role of surgery'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For locoregionally advanced, nonmetastatic (eg, T3N1 or T4) NEC outside of the esophagus, we individualize the use of radiation therapy as a component of multimodality therapy (chemotherapy with or without surgery) depending on location and risk of locoregional recurrence. Given the aggressive nature of NEC, we often use neoadjuvant rather than adjuvant combined modality treatment; however, many cases are diagnosed only after surgical resection. (See <a class="local">'Benefit of radiotherapy'</a> above and <a class="local">'Integration of local therapy'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For localized or locoregional esophageal NEC, we suggest concurrent chemoradiotherapy plus chemotherapy rather than surgery plus chemotherapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Role of surgery'</a> above and <a class="local">'Integration of local therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Prophylactic cranial irradiation is not required. (See <a class="local">'Prophylactic cranial irradiation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of metastatic NEC</strong> – For most patients, we suggest standard palliative chemotherapy with <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> or <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> combined with <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Rapid referral is appropriate given the aggressive nature of these tumors. (See <a class="local">'Initial chemotherapy'</a> above.)</p><p></p><p class="bulletIndent1">We aim for four to six cycles of therapy, but if a patient is still responding and tolerating treatment well continuation of chemotherapy to at least maximal response is appropriate.</p><p></p><p class="bulletIndent1">The decision to pursue metastasectomy must be individualized. (See <a class="local">'Role of metastasectomy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of recurrent NEC</strong> – Patients may benefit from retreatment with platinum/<a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a> if relapse occurs at least three to six months after discontinuation of first-line treatment. For patients with platinum-refractory disease, other options include <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> with or without capecitabine-, fluoropyrimidine-, irinotecan-, and oxaliplatin-based regimens and immunotherapy. Patients whose tumors have deficient mismatch repair are much more likely to benefit from immunotherapy than are unselected patients. (See <a class="local">'Second-line chemotherapy'</a> above and <a class="local">'Immunotherapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of</strong> <strong>NET G3</strong> – A minority of high-grade NEN, particularly those of pancreatic origin, have a Ki-67 index &gt;20 percent but relatively well-differentiated histology (NET G3). Prognosis is better compared with NEC.(See <a class="local">'High-grade, well-differentiated tumors (NET G3)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with apparently localized potentially resectable disease we suggest resection rather than nonoperative therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). For most patients we suggest not pursuing adjuvant chemotherapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Localized disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most patients with unresectable and/or metastatic disease, we suggest temozolomide-based chemotherapy or FOLFOX  (<a class="graphic graphic_table graphicRef50132" href="/z/d/graphic/50132.html" rel="external">table 4</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). However, other therapies such as <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> or a somatostatin analog (for somatostatin receptor positive disease) could be options for tumors with favorable tumor biology. We do not generally treat with platinum-based first-line chemotherapy, unless the disease is exceptionally aggressive at outset. (See <a class="local">'Advanced disease'</a> above.)</p><p></p><p class="bulletIndent2">Peptide receptor radioligand therapy is also a reasonable option for those with somatostatin receptor expressing tumors. (See <a class="local">'Peptide receptor radioligand therapy'</a> above.)</p><p></p><p class="bulletIndent2">The role of liver-directed therapy for hepatic-predominant NET G3 is uncertain, as the available data are very limited. However, as with NET G2, some patients with limited, liver-isolated metastases may be appropriate candidates for hepatic metastasectomy.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Klimstra DS, Modlin IR, Coppola D, et al. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 2010; 39:707.</a></li><li class="breakAll">Rindi G, Arnold R, Bosman FT, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: WHO Classification of Tumours of the Digestive System, 4th ed, Bosman TF, Carneiro F, Hruban RH, Theise ND (Eds), International Agency for Research on cancer (IARC), Lyon 2010. p.13.</li><li class="breakAll">Hruban RH, Pitman MB, Klimstra DS. Tumors of the pancreas, ARP/AFIP, Washington, DC 2007. p.422.</li><li><a class="nounderline abstract_t">La Rosa S, Inzani F, Vanoli A, et al. Histologic characterization and improved prognostic evaluation of 209 gastric neuroendocrine neoplasms. Hum Pathol 2011; 42:1373.</a></li><li><a class="nounderline abstract_t">Panzuto F, Boninsegna L, Fazio N, et al. Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J Clin Oncol 2011; 29:2372.</a></li><li><a class="nounderline abstract_t">Sorbye H, Strosberg J, Baudin E, et al. Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer 2014; 120:2814.</a></li><li><a class="nounderline abstract_t">Vélayoudom-Céphise FL, Duvillard P, Foucan L, et al. Are G3 ENETS neuroendocrine neoplasms heterogeneous? Endocr Relat Cancer 2013; 20:649.</a></li><li><a class="nounderline abstract_t">Scoazec J-Y, Couvelard A, Monges G, et al. Well-differentiated grade 3 digestive neuroendocrine tumors: Myth or reality? The PRONET study group. J Clin Oncol 2012; 30S: ASCO #4129.</a></li><li><a class="nounderline abstract_t">Lepage C, Ciccolallo L, De Angelis R, et al. European disparities in malignant digestive endocrine tumours survival. Int J Cancer 2010; 126:2928.</a></li><li><a class="nounderline abstract_t">Basturk O, Yang Z, Tang LH, et al. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol 2015; 39:683.</a></li><li><a class="nounderline abstract_t">Heetfeld M, Chougnet CN, Olsen IH, et al. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer 2015; 22:657.</a></li><li><a class="nounderline abstract_t">Coriat R, Walter T, Terris B, et al. Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement. Oncologist 2016; 21:1191.</a></li><li class="breakAll">Klimstra DS, Kloppell G, La Rosa S, Rindi G. Classification of neuroendocrine neoplasms of the digestive system. In: WHO Classification of Tumours: Digestive System Tumours, 5th ed, WHO Classification of Tumours Editorial Board (Ed), International Agency for Research on Cancer, Lyon 2019. p.16.</li><li><a class="nounderline abstract_t">Shia J, Tang LH, Weiser MR, et al. Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity? Am J Surg Pathol 2008; 32:719.</a></li><li><a class="nounderline abstract_t">La Rosa S, Marando A, Furlan D, et al. Colorectal poorly differentiated neuroendocrine carcinomas and mixed adenoneuroendocrine carcinomas: insights into the diagnostic immunophenotype, assessment of methylation profile, and search for prognostic markers. Am J Surg Pathol 2012; 36:601.</a></li><li><a class="nounderline abstract_t">Jiang SX, Mikami T, Umezawa A, et al. Gastric large cell neuroendocrine carcinomas: a distinct clinicopathologic entity. Am J Surg Pathol 2006; 30:945.</a></li><li><a class="nounderline abstract_t">Dasari A, Mehta K, Byers LA, et al. Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases. Cancer 2018; 124:807.</a></li><li><a class="nounderline abstract_t">Basturk O, Tang L, Hruban RH, et al. Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 cases. Am J Surg Pathol 2014; 38:437.</a></li><li><a class="nounderline abstract_t">Volante M, Birocco N, Gatti G, et al. Extrapulmonary neuroendocrine small and large cell carcinomas: a review of controversial diagnostic and therapeutic issues. Hum Pathol 2014; 45:665.</a></li><li><a class="nounderline abstract_t">Matsui K, Jin XM, Kitagawa M, Miwa A. Clinicopathologic features of neuroendocrine carcinomas of the stomach: appraisal of small cell and large cell variants. Arch Pathol Lab Med 1998; 122:1010.</a></li><li><a class="nounderline abstract_t">Korse CM, Taal BG, van Velthuysen ML, Visser O. Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer registry. Eur J Cancer 2013; 49:1975.</a></li><li><a class="nounderline abstract_t">Walenkamp AM, Sonke GS, Sleijfer DT. Clinical and therapeutic aspects of extrapulmonary small cell carcinoma. Cancer Treat Rev 2009; 35:228.</a></li><li><a class="nounderline abstract_t">Brennan SM, Gregory DL, Stillie A, et al. Should extrapulmonary small cell cancer be managed like small cell lung cancer? Cancer 2010; 116:888.</a></li><li><a class="nounderline abstract_t">Terashima T, Morizane C, Hiraoka N, et al. Comparison of chemotherapeutic treatment outcomes of advanced extrapulmonary neuroendocrine carcinomas and advanced small-cell lung carcinoma. Neuroendocrinology 2012; 96:324.</a></li><li><a class="nounderline abstract_t">Wong YN, Jack RH, Mak V, et al. The epidemiology and survival of extrapulmonary small cell carcinoma in South East England, 1970-2004. BMC Cancer 2009; 9:209.</a></li><li><a class="nounderline abstract_t">Conte B, George B, Overman M, et al. High-Grade Neuroendocrine Colorectal Carcinomas: A Retrospective Study of 100 Patients. Clin Colorectal Cancer 2016; 15:e1.</a></li><li><a class="nounderline abstract_t">Bergsland EK, Roy R, Stephens P, et al. Genomic profiling to distinguish poorly differentiated neuroendocrine carcinomas arising in different sites. J Clin Oncol 2016; 34S: ASCO #4020.</a></li><li><a class="nounderline abstract_t">Hijioka S, Hosoda W, Matsuo K, et al. Rb Loss and KRAS Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study. Clin Cancer Res 2017; 23:4625.</a></li><li><a class="nounderline abstract_t">Puccini A, Poorman K, Salem ME, et al. Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). Clin Cancer Res 2020; 26:5943.</a></li><li><a class="nounderline abstract_t">George J, Lim JS, Jang SJ, et al. Comprehensive genomic profiles of small cell lung cancer. Nature 2015; 524:47.</a></li><li><a class="nounderline abstract_t">Scoazec JY, Couvelard A, Monges G, et al. Professional Practices and Diagnostic Issues in Neuroendocrine Tumour Pathology: Results of a Prospective One-Year Survey Among French Pathologists (the PRONET Study). Neuroendocrinology 2016.</a></li><li><a class="nounderline abstract_t">Walter T, Tougeron D, Baudin E, et al. Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort. Eur J Cancer 2017; 79:158.</a></li><li class="breakAll">Basturk O, Yang Z, Tang LH, et al. Increased (&gt;20%) KI67 proliferation index in morphologically well differentiated pancreatic neuroendocrine tumors (pannets) correlates with decreased overall survival. 102nd United States and Canadian Academy of Pathology Annual Meeting 2013. Baltimore, MD. Laboratory Investigation 2013; 93:423A.</li><li><a class="nounderline abstract_t">Elvebakken H, Perren A, Scoazec JY, et al. A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations. Neuroendocrinology 2021; 111:883.</a></li><li><a class="nounderline abstract_t">Sorbye H, Welin S, Langer SW, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol 2013; 24:152.</a></li><li><a class="nounderline abstract_t">Kang H, O'Connell JB, Leonardi MJ, et al. Rare tumors of the colon and rectum: a national review. Int J Colorectal Dis 2007; 22:183.</a></li><li><a class="nounderline abstract_t">Gastrointestinal Pathology Study Group of Korean Society of Pathologists, Cho MY, Kim JM, et al. Current Trends of the Incidence and Pathological Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Korea 2000-2009: Multicenter Study. Cancer Res Treat 2012; 44:157.</a></li><li><a class="nounderline abstract_t">Tsai HJ, Wu CC, Tsai CR, et al. The epidemiology of neuroendocrine tumors in Taiwan: a nation-wide cancer registry-based study. PLoS One 2013; 8:e62487.</a></li><li><a class="nounderline abstract_t">Zhang X, Ma L, Bao H, et al. Clinical, pathological and prognostic characteristics of gastroenteropancreatic neuroendocrine neoplasms in China: a retrospective study. BMC Endocr Disord 2014; 14:54.</a></li><li><a class="nounderline abstract_t">Boyar Cetinkaya R, Aagnes B, Thiis-Evensen E, et al. Trends in Incidence of Neuroendocrine Neoplasms in Norway: A Report of 16,075 Cases from 1993 through 2010. Neuroendocrinology 2017; 104:1.</a></li><li><a class="nounderline abstract_t">Shafqat H, Ali S, Salhab M, Olszewski AJ. Survival of patients with neuroendocrine carcinoma of the colon and rectum: a population-based analysis. Dis Colon Rectum 2015; 58:294.</a></li><li><a class="nounderline abstract_t">Ku GY, Minsky BD, Rusch VW, et al. Small-cell carcinoma of the esophagus and gastroesophageal junction: review of the Memorial Sloan-Kettering experience. Ann Oncol 2008; 19:533.</a></li><li><a class="nounderline abstract_t">Lv J, Liang J, Wang J, et al. Primary small cell carcinoma of the esophagus. J Thorac Oncol 2008; 3:1460.</a></li><li><a class="nounderline abstract_t">Tanemura H, Ohshita H, Kanno A, et al. A patient with small-cell carcinoma of the stomach with long survival after percutaneous microwave coagulating therapy (PMCT) for liver metastasis. Int J Clin Oncol 2002; 7:128.</a></li><li><a class="nounderline abstract_t">Brenner B, Tang LH, Shia J, et al. Small cell carcinomas of the gastrointestinal tract: clinicopathological features and treatment approach. Semin Oncol 2007; 34:43.</a></li><li><a class="nounderline abstract_t">Yaziji H, Broghamer WL Jr. Primary small cell undifferentiated carcinoma of the rectum associated with ulcerative colitis. South Med J 1996; 89:921.</a></li><li><a class="nounderline abstract_t">Tang LH, Untch BR, Reidy DL, et al. Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas. Clin Cancer Res 2016; 22:1011.</a></li><li><a class="nounderline abstract_t">Brenner B, Tang LH, Klimstra DS, Kelsen DP. Small-cell carcinomas of the gastrointestinal tract: a review. J Clin Oncol 2004; 22:2730.</a></li><li><a class="nounderline abstract_t">Brenner B, Shah MA, Gonen M, et al. Small-cell carcinoma of the gastrointestinal tract: a retrospective study of 64 cases. Br J Cancer 2004; 90:1720.</a></li><li><a class="nounderline abstract_t">Yamaguchi T, Machida N, Morizane C, et al. Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system. Cancer Sci 2014; 105:1176.</a></li><li><a class="nounderline abstract_t">Casas F, Ferrer F, Farrús B, et al. Primary small cell carcinoma of the esophagus: a review of the literature with emphasis on therapy and prognosis. Cancer 1997; 80:1366.</a></li><li><a class="nounderline abstract_t">Briggs JC, Ibrahim NB. Oat cell carcinomas of the oesophagus: a clinico-pathological study of 23 cases. Histopathology 1983; 7:261.</a></li><li><a class="nounderline abstract_t">Janson ET, Sorbye H, Welin S, et al. Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncol 2014; 53:1284.</a></li><li><a class="nounderline abstract_t">Gupta A, Duque M, Saif MW. Treatment of poorly differentiated neuroendocrine carcinoma of the pancreas. JOP 2013; 14:381.</a></li><li><a class="nounderline abstract_t">Mitry E, Baudin E, Ducreux M, et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 1999; 81:1351.</a></li><li class="breakAll">SEER*Stat Database: Incidence—SEER 9 Regs Research Data, November 2011 submission (1973-2010). Bethesda, MD: National Cancer Institute, Cancer Statistics Branch; 2013. www.seer.cancer.gov.</li><li><a class="nounderline abstract_t">Milione M, Maisonneuve P, Spada F, et al. The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories. Neuroendocrinology 2017; 104:85.</a></li><li><a class="nounderline abstract_t">Cicin I, Karagol H, Uzunoglu S, et al. Extrapulmonary small-cell carcinoma compared with small-cell lung carcinoma: a retrospective single-center study. Cancer 2007; 110:1068.</a></li><li><a class="nounderline abstract_t">Joyce EA, Kavanagh J, Sheehy N, et al. Imaging features of extrapulmonary small cell carcinoma. Clin Radiol 2013; 68:953.</a></li><li><a class="nounderline abstract_t">La Rosa S, Sessa F. High-grade poorly differentiated neuroendocrine carcinomas of the gastroenteropancreatic system: from morphology to proliferation and back. Endocr Pathol 2014; 25:193.</a></li><li><a class="nounderline abstract_t">La Rosa S, Sessa F, Uccella S. Mixed Neuroendocrine-Nonneuroendocrine Neoplasms (MiNENs): Unifying the Concept of a Heterogeneous Group of Neoplasms. Endocr Pathol 2016; 27:284.</a></li><li class="breakAll">La Rosa S, Klimstra DS. Pancreatic MiNENs. In: WHO Classification of Tumours: Digestive System Tumours, 5th ed, WHO Classification of Tumours Editorial Board (Ed), International Agency for Research on Cancer, Lyon 2019. p.370.</li><li><a class="nounderline abstract_t">Ho KJ, Herrera GA, Jones JM, Alexander CB. Small cell carcinoma of the esophagus: evidence for a unified histogenesis. Hum Pathol 1984; 15:460.</a></li><li><a class="nounderline abstract_t">Sidhu GS. The endodermal origin of digestive and respiratory tract APUD cells. Histopathologic evidence and a review of the literature. Am J Pathol 1979; 96:5.</a></li><li><a class="nounderline abstract_t">Frizziero M, Wang X, Chakrabarty B, et al. Retrospective study on mixed neuroendocrine non-neuroendocrine neoplasms from five European centres. World J Gastroenterol 2019; 25:5991.</a></li><li><a class="nounderline abstract_t">de Mestier L, Cros J, Neuzillet C, et al. Digestive System Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms. Neuroendocrinology 2017; 105:412.</a></li><li><a class="nounderline abstract_t">Ishida M, Sekine S, Fukagawa T, et al. Neuroendocrine carcinoma of the stomach: morphologic and immunohistochemical characteristics and prognosis. Am J Surg Pathol 2013; 37:949.</a></li><li><a class="nounderline abstract_t">Wick MR. Immunohistology of neuroendocrine and neuroectodermal tumors. Semin Diagn Pathol 2000; 17:194.</a></li><li><a class="nounderline abstract_t">Tang LH, Basturk O, Sue JJ, Klimstra DS. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas. Am J Surg Pathol 2016; 40:1192.</a></li><li><a class="nounderline abstract_t">Sorbye H, Kong G, Grozinsky-Glasberg S. PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3). Endocr Relat Cancer 2020; 27:R67.</a></li><li><a class="nounderline abstract_t">Raj N, Valentino E, Capanu M, et al. Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology: Well Differentiated Versus Poorly Differentiated. Pancreas 2017; 46:296.</a></li><li><a class="nounderline abstract_t">Rindi G, Klöppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006; 449:395.</a></li><li><a class="nounderline abstract_t">Rindi G, Klöppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007; 451:757.</a></li><li class="breakAll">Ohike N, Adsay NV, La Rosa S, et al. Mixed neuroendocrine-non-neuroendocrine neoplasms. In: WHO Classification of Tumours of Endocrine Organs, 4th ed, Lloyd RV, Osamura RY, Kloppel G, Rosai J (Eds), IARC Press, Lyon 2017. p.238.</li><li class="breakAll">Rindi G, Arnold R, Bosman FT, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: WHO Classification Tumours of the Digestive System, 4th ed, Bosman TF, Carneiro F, Hruban RH, Theise ND (Eds), International Agency for Reseach on Cancer (IARC), Lyon 2010. p.13.</li><li class="breakAll">AJCC Cancer Staging Manual, 8th ed, Amin MB (Ed), Springer, Chicago 2017.</li><li class="breakAll">AJCC Cancer Staging Manual, 7th ed, Edge SB, Byrd DB, Compton CC, et al. (Eds), Springer-Verlag, New York 2010.</li><li><a class="nounderline abstract_t">Venizelos A, Elvebakken H, Perren A, et al. The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer 2021; 29:1.</a></li><li><a class="nounderline abstract_t">Lee SS, Lee JL, Ryu MH, et al. Extrapulmonary small cell carcinoma: single center experience with 61 patients. Acta Oncol 2007; 46:846.</a></li><li><a class="nounderline abstract_t">Faggiano A, Sabourin JC, Ducreux M, et al. Pulmonary and extrapulmonary poorly differentiated large cell neuroendocrine carcinomas: diagnostic and prognostic features. Cancer 2007; 110:265.</a></li><li><a class="nounderline abstract_t">Strosberg JR, Coppola D, Klimstra DS, et al. The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas 2010; 39:799.</a></li><li><a class="nounderline abstract_t">Meng MB, Zaorsky NG, Jiang C, et al. Radiotherapy and chemotherapy are associated with improved outcomes over surgery and chemotherapy in the management of limited-stage small cell esophageal carcinoma. Radiother Oncol 2013; 106:317.</a></li><li><a class="nounderline abstract_t">Garcia-Carbonero R, Sorbye H, Baudin E, et al. ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas. Neuroendocrinology 2016; 103:186.</a></li><li><a class="nounderline abstract_t">Haugvik SP, Janson ET, Österlund P, et al. Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma: A Nordic Multicenter Comparative Study. Ann Surg Oncol 2016; 23:1721.</a></li><li><a class="nounderline abstract_t">Crippa S, Partelli S, Bassi C, et al. Long-term outcomes and prognostic factors in neuroendocrine carcinomas of the pancreas: Morphology matters. Surgery 2016; 159:862.</a></li><li><a class="nounderline abstract_t">Deng HY, Ni PZ, Wang YC, et al. Neuroendocrine carcinoma of the esophagus: clinical characteristics and prognostic evaluation of 49 cases with surgical resection. J Thorac Dis 2016; 8:1250.</a></li><li><a class="nounderline abstract_t">Shen C, Chen H, Chen H, et al. Surgical treatment and prognosis of gastric neuroendocrine neoplasms: a single-center experience. BMC Gastroenterol 2016; 16:111.</a></li><li><a class="nounderline abstract_t">Xie JW, Sun YQ, Feng CY, et al. Evaluation of clinicopathological factors related to the prognosis of gastric neuroendocrine carcinoma. Eur J Surg Oncol 2016; 42:1464.</a></li><li><a class="nounderline abstract_t">Merola E, Rinke A, Partelli S, et al. Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms? Ann Surg Oncol 2020; 27:1348.</a></li><li><a class="nounderline abstract_t">Pommergaard HC, Nielsen K, Sorbye H, et al. Surgery of the primary tumour in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine-non-neuroendocrine neoplasms. J Neuroendocrinol 2021; 33:e12967.</a></li><li><a class="nounderline abstract_t">Thornblade LW, Warner SG, Melstrom L, et al. Does surgery provide a survival advantage in non-disseminated poorly differentiated gastroenteropancreatic neuroendocrine neoplasms? Surgery 2021; 169:1417.</a></li><li><a class="nounderline abstract_t">Ziogas IA, Tasoudis PT, Borbon LC, et al. Surgical Management of G3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Systematic Review and Meta-analysis. Ann Surg Oncol 2023; 30:148.</a></li><li><a class="nounderline abstract_t">Dasari A, Shen C, Devabhaktuni A, et al. Survival According to Primary Tumor Location, Stage, and Treatment Patterns in Locoregional Gastroenteropancreatic High-grade Neuroendocrine Carcinomas. Oncologist 2022; 27:299.</a></li><li class="breakAll">National Comprehensive Cancer Network (NCCN) guidelines available online at https://www.nccn.org/professionals/physician_gls/ (Accessed on March 25, 2021).</li><li><a class="nounderline abstract_t">Schmitz R, Mao R, Moris D, et al. Impact of Postoperative Chemotherapy on the Survival of Patients with High-Grade Gastroenteropancreatic Neuroendocrine Carcinoma. Ann Surg Oncol 2021; 28:114.</a></li><li><a class="nounderline abstract_t">Mao R, Li K, Cai JQ, et al. Adjuvant Chemotherapy Versus Observation Following Resection for Patients With Nonmetastatic Poorly Differentiated Colorectal Neuroendocrine Carcinomas. Ann Surg 2021; 274:e126.</a></li><li><a class="nounderline abstract_t">Fields AC, Lu P, Vierra BM, et al. Survival in Patients with High-Grade Colorectal Neuroendocrine Carcinomas: The Role of Surgery and Chemotherapy. Ann Surg Oncol 2019; 26:1127.</a></li><li><a class="nounderline abstract_t">Lin JP, Zhao YJ, He QL, et al. Adjuvant chemotherapy for patients with gastric neuroendocrine carcinomas or mixed adenoneuroendocrine carcinomas. Br J Surg 2020; 107:1163.</a></li><li><a class="nounderline abstract_t">Erstad DJ, Dasari A, Taggart MW, et al. Prognosis for Poorly Differentiated, High-Grade Rectal Neuroendocrine Carcinomas. Ann Surg Oncol 2022; 29:2539.</a></li><li><a class="nounderline abstract_t">Rossi A, Di Maio M, Chiodini P, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol 2012; 30:1692.</a></li><li><a class="nounderline abstract_t">Kunz PL, Reidy-Lagunes D, Anthony LB, et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas 2013; 42:557.</a></li><li><a class="nounderline abstract_t">Fazio N, Spada F, Giovannini M. Chemotherapy in gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC): a critical view. Cancer Treat Rev 2013; 39:270.</a></li><li><a class="nounderline abstract_t">Zhang P, Li J, Li J, et al. Etoposide and cisplatin versus irinotecan and cisplatin as the first-line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: A randomized phase 2 study. Cancer 2020; 126 Suppl 9:2086.</a></li><li><a class="nounderline abstract_t">Morizane C, Machida N, Honma Y, et al. Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial. JAMA Oncol 2022; 8:1447.</a></li><li><a class="nounderline abstract_t">Galleberg RB, Knigge U, Tiensuu Janson E, et al. Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas. Eur J Surg Oncol 2017; 43:1682.</a></li><li><a class="nounderline abstract_t">Welin S, Sorbye H, Sebjornsen S, et al. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer 2011; 117:4617.</a></li><li><a class="nounderline abstract_t">Olsen IH, Sørensen JB, Federspiel B, et al. Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas. ScientificWorldJournal 2012; 2012:170496.</a></li><li><a class="nounderline abstract_t">de Herder WW, van der Lely AJ, Lamberts SW. Somatostatin analogue treatment of neuroendocrine tumours. Postgrad Med J 1996; 72:403.</a></li><li><a class="nounderline abstract_t">Hadoux J, Malka D, Planchard D, et al. Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma. Endocr Relat Cancer 2015; 22:289.</a></li><li><a class="nounderline abstract_t">Chan DL, Bergsland EK, Chan JA, et al. Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review. Oncologist 2021; 26:950.</a></li><li><a class="nounderline abstract_t">Walter T, Lievre A, Coriat R, et al. Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial. Lancet Oncol 2023; 24:297.</a></li><li><a class="nounderline abstract_t">Hentic O, Hammel P, Couvelard A, et al. FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3. Endocr Relat Cancer 2012; 19:751.</a></li><li class="breakAll">McNamara MG, et al. NET-02: A multicenter, randomized, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC) J Clin Oncol 40, 2022 (suppl 16; abstr 4005). Abstract available at https://meetings.asco.org/2022-asco-annual-meeting/14362?presentation=208030#208030 (Accessed on June 21, 2022).</li><li><a class="nounderline abstract_t">Zhu J, Strosberg JR, Dropkin E, Strickler JH. Treatment of High-Grade Metastatic Pancreatic Neuroendocrine Carcinoma with FOLFIRINOX. J Gastrointest Cancer 2015; 46:166.</a></li><li><a class="nounderline abstract_t">Olsen IH, Knigge U, Federspiel B, et al. Topotecan monotherapy in heavily pretreated patients with progressive advanced stage neuroendocrine carcinomas. J Cancer 2014; 5:628.</a></li><li><a class="nounderline abstract_t">Vijayvergia N, Dasari A, Ross EA, et al. Pembrolizumab (P) monotherapy in patients with previously treated metastatic high grade neuroendocrine neoplasms (HG-NENs). J Clin Oncol 2018; 36S: ASCO #4104.</a></li><li><a class="nounderline abstract_t">Vijayvergia N, Dasari A, Deng M, et al. Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials. Br J Cancer 2020; 122:1309.</a></li><li><a class="nounderline abstract_t">Yao JC, Strosberg J, Fazio N, et al. Activity &amp; Safety of Spartalizumab (PDR001) in Patients (pts) With Advanced Neuroendocrine Tumors (NET) of Pancreatic (Pan), Gastrointestinal (GI), or thoracic (T) origin, &amp; gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx). Ann Oncol 2018; 29S: ESMO #3442.</a></li><li><a class="nounderline abstract_t">Chan DL, Rodriguez-Freixinos V, Doherty M, et al. Avelumab in unresectable/metastatic, progressive, grade 2-3 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials. Eur J Cancer 2022; 169:74.</a></li><li><a class="nounderline abstract_t">Patel SP, Mayerson E, Chae YK, et al. A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohort. Cancer 2021; 127:3194.</a></li><li><a class="nounderline abstract_t">Al-Toubah T, Halfdanarson T, Gile J, et al. Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms. ESMO Open 2022; 7:100364.</a></li><li><a class="nounderline abstract_t">Capdevila J, Arqués O, Hernández Mora JR, et al. Epigenetic EGFR Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas. Clin Cancer Res 2020; 26:902.</a></li><li><a class="nounderline abstract_t">Capdevila J, Teule A, Lopez C, et al. A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601). Ann Oncol 2020; 31S:ESMO #11570.</a></li><li><a class="nounderline abstract_t">Riesco-Martinez MC, Capdevila J, Alonso V, et al. Nivolumab plus platinum-doublet chemotherapy as first-line therapy in unresectable, locally advanced or metastatic G3 neuroendocrine Neoplasms (NENs) of the gastroenteropancreatic (GEP) tract or unknown (UK) origin: Preliminary results from the phase II NICE-NEC trial (GETNE T1913). Ann Oncol 2021; 32S:S906.</a></li><li><a class="nounderline abstract_t">Girard N, Mazieres J, Otto J, et al. Nivolumab (nivo) ± ipilimumab (ipi) in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) (GCO-001 NIPINEC). Ann Oncol 2021; 32S:S1283.</a></li><li><a class="nounderline abstract_t">Sahnane N, Furlan D, Monti M, et al. Microsatellite unstable gastrointestinal neuroendocrine carcinomas: a new clinicopathologic entity. Endocr Relat Cancer 2015; 22:35.</a></li><li><a class="nounderline abstract_t">Klempner SJ, Gershenhorn B, Tran P, et al. BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy. Cancer Discov 2016; 6:594.</a></li><li><a class="nounderline abstract_t">Smith JD, Reidy DL, Goodman KA, et al. A retrospective review of 126 high-grade neuroendocrine carcinomas of the colon and rectum. Ann Surg Oncol 2014; 21:2956.</a></li><li><a class="nounderline abstract_t">Burke AB, Shekitka KM, Sobin LH. Small cell carcinomas of the large intestine. Am J Clin Pathol 1991; 95:315.</a></li><li><a class="nounderline abstract_t">Hung SS. Small cell carcinoma of the colon. A case report and literature review. J Clin Gastroenterol 1989; 11:335.</a></li><li><a class="nounderline abstract_t">Izuishi K, Arai T, Ochiai A, et al. Long-term survival in advanced small cell carcinoma of the colorectum: report of a case. Surg Today 2002; 32:72.</a></li><li><a class="nounderline abstract_t">Aytac E, Ozdemir Y, Ozuner G. Long term outcomes of neuroendocrine carcinomas (high-grade neuroendocrine tumors) of the colon, rectum, and anal canal. J Visc Surg 2014; 151:3.</a></li><li><a class="nounderline abstract_t">Lamarca A, Walter T, Pavel M, et al. Design and Validation of the GI-NEC Score to Prognosticate Overall Survival in Patients With High-Grade Gastrointestinal Neuroendocrine Carcinomas. J Natl Cancer Inst 2017; 109.</a></li><li><a class="nounderline abstract_t">Panzuto F, Merola E, Pavel ME, et al. Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome. Oncologist 2017; 22:409.</a></li><li><a class="nounderline abstract_t">Strosberg JR, Cheema A, Weber J, et al. Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. J Clin Oncol 2011; 29:3044.</a></li><li><a class="nounderline abstract_t">Mizuno Y, Kudo A, Akashi T, et al. Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms. J Cancer Res Clin Oncol 2018; 144:1155.</a></li><li><a class="nounderline abstract_t">Spada F, Maisonneuve P, Fumagalli C, et al. Temozolomide alone or in combination with capecitabine in patients with advanced neuroendocrine neoplasms: an Italian multicenter real-world analysis. Endocrine 2021; 72:268.</a></li><li><a class="nounderline abstract_t">Liu AJ, Ueberroth BE, McGarrah PW, et al. Treatment Outcomes of Well-Differentiated High-Grade Neuroendocrine Tumors. Oncologist 2021; 26:383.</a></li><li><a class="nounderline abstract_t">Apostolidis L, Dal Buono A, Merola E, et al. Multicenter Analysis of Treatment Outcomes for Systemic Therapy in Well Differentiated Grade 3 Neuroendocrine Tumors (NET G3). Cancers (Basel) 2021; 13.</a></li><li><a class="nounderline abstract_t">Sharpe SM, In H, Winchester DJ, et al. Surgical resection provides an overall survival benefit for patients with small pancreatic neuroendocrine tumors. J Gastrointest Surg 2015; 19:117.</a></li><li><a class="nounderline abstract_t">Haugvik SP, Kaemmerer D, Gaujoux S, et al. Pathology and Surgical Treatment of High-Grade Pancreatic Neuroendocrine Carcinoma: an Evolving Landscape. Curr Oncol Rep 2016; 18:28.</a></li><li><a class="nounderline abstract_t">Thang SP, Lung MS, Kong G, et al. Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis. Eur J Nucl Med Mol Imaging 2018; 45:262.</a></li><li><a class="nounderline abstract_t">Carlsen EA, Fazio N, Granberg D, et al. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study. Endocr Relat Cancer 2019; 26:227.</a></li><li><a class="nounderline abstract_t">Zhang J, Kulkarni HR, Singh A, et al. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients. J Nucl Med 2019; 60:377.</a></li><li><a class="nounderline abstract_t">Nicolini S, Severi S, Ianniello A, et al. Investigation of receptor radionuclide therapy with 177Lu-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index. Eur J Nucl Med Mol Imaging 2018; 45:923.</a></li></ol></div><div id="topicVersionRevision">Topic 98796 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20664470" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20664470" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20664470" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21531442" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Histologic characterization and improved prognostic evaluation of 209 gastric neuroendocrine neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21555696" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24771552" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Gastroenteropancreatic high-grade neuroendocrine carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23845449" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Are G3 ENETS neuroendocrine neoplasms heterogeneous?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : . Well-differentiated grade 3 digestive neuroendocrine tumors: Myth or reality? The PRONET study group</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19569047" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : European disparities in malignant digestive endocrine tumours survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25723112" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26113608" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27401895" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27401895" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18360283" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22314183" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Colorectal poorly differentiated neuroendocrine carcinomas and mixed adenoneuroendocrine carcinomas: insights into the diagnostic immunophenotype, assessment of methylation profile, and search for prognostic markers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16861964" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Gastric large cell neuroendocrine carcinomas: a distinct clinicopathologic entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29211313" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24503751" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23806528" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Extrapulmonary neuroendocrine small and large cell carcinomas: a review of controversial diagnostic and therapeutic issues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9822131" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Clinicopathologic features of neuroendocrine carcinomas of the stomach: appraisal of small cell and large cell variants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23352435" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19068273" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Clinical and therapeutic aspects of extrapulmonary small cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20052730" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Should extrapulmonary small cell cancer be managed like small cell lung cancer?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22572060" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Comparison of chemotherapeutic treatment outcomes of advanced extrapulmonary neuroendocrine carcinomas and advanced small-cell lung carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19563623" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The epidemiology and survival of extrapulmonary small cell carcinoma in South East England, 1970-2004.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26810202" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : High-Grade Neuroendocrine Colorectal Carcinomas: A Retrospective Study of 100 Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Genomic profiling to distinguish poorly differentiated neuroendocrine carcinomas arising in different sites</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28455360" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Rb Loss and KRAS Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32883742" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26168399" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Comprehensive genomic profiles of small cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27442514" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Professional Practices and Diagnostic Issues in Neuroendocrine Tumour Pathology: Results of a Prospective One-Year Survey Among French Pathologists (the PRONET Study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28501762" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28501762" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33002892" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22967994" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16845516" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Rare tumors of the colon and rectum: a national review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23091441" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Current Trends of the Incidence and Pathological Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Korea 2000-2009: Multicenter Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23614051" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The epidemiology of neuroendocrine tumors in Taiwan: a nation-wide cancer registry-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25001493" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Clinical, pathological and prognostic characteristics of gastroenteropancreatic neuroendocrine neoplasms in China: a retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26562558" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Trends in Incidence of Neuroendocrine Neoplasms in Norway: A Report of 16,075 Cases from 1993 through 2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25664707" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Survival of patients with neuroendocrine carcinoma of the colon and rectum: a population-based analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17947223" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Small-cell carcinoma of the esophagus and gastroesophageal junction: review of the Memorial Sloan-Kettering experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19057273" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Primary small cell carcinoma of the esophagus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12018111" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : A patient with small-cell carcinoma of the stomach with long survival after percutaneous microwave coagulating therapy (PMCT) for liver metastasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17270665" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Small cell carcinomas of the gastrointestinal tract: clinicopathological features and treatment approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8790320" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Primary small cell undifferentiated carcinoma of the rectum associated with ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26482044" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15226341" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Small-cell carcinomas of the gastrointestinal tract: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15150595" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Small-cell carcinoma of the gastrointestinal tract: a retrospective study of 64 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24975505" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9338459" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Primary small cell carcinoma of the esophagus: a review of the literature with emphasis on therapy and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6133829" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Oat cell carcinomas of the oesophagus: a clinico-pathological study of 23 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25140861" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23846932" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Treatment of poorly differentiated neuroendocrine carcinoma of the pancreas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10604732" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10604732" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26943788" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17614337" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Extrapulmonary small-cell carcinoma compared with small-cell lung carcinoma: a retrospective single-center study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23790688" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Imaging features of extrapulmonary small cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24715269" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : High-grade poorly differentiated neuroendocrine carcinomas of the gastroenteropancreatic system: from morphology to proliferation and back.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27169712" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Mixed Neuroendocrine-Nonneuroendocrine Neoplasms (MiNENs): Unifying the Concept of a Heterogeneous Group of Neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27169712" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Mixed Neuroendocrine-Nonneuroendocrine Neoplasms (MiNENs): Unifying the Concept of a Heterogeneous Group of Neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6327495" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Small cell carcinoma of the esophagus: evidence for a unified histogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37740" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : The endodermal origin of digestive and respiratory tract APUD cells. Histopathologic evidence and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31660035" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Retrospective study on mixed neuroendocrine non-neuroendocrine neoplasms from five European centres.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28803232" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Digestive System Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23759931" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Neuroendocrine carcinoma of the stomach: morphologic and immunohistochemical characteristics and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10968705" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Immunohistology of neuroendocrine and neuroectodermal tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27259015" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31846429" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27759713" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology: Well Differentiated Versus Poorly Differentiated.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16967267" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17674042" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17674042" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17674042" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17674042" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17674042" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34647903" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17653910" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Extrapulmonary small cell carcinoma: single center experience with 61 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17569104" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Pulmonary and extrapulmonary poorly differentiated large cell neuroendocrine carcinomas: diagnostic and prognostic features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20664477" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23498325" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Radiotherapy and chemotherapy are associated with improved outcomes over surgery and chemotherapy in the management of limited-stage small cell esophageal carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26731334" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26678407" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma: A Nordic Multicenter Comparative Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26602841" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Long-term outcomes and prognostic factors in neuroendocrine carcinomas of the pancreas: Morphology matters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27293844" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Neuroendocrine carcinoma of the esophagus: clinical characteristics and prognostic evaluation of 49 cases with surgical resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27613657" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Surgical treatment and prognosis of gastric neuroendocrine neoplasms: a single-center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27570115" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Evaluation of clinicopathological factors related to the prognosis of gastric neuroendocrine carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31720931" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33769624" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Surgery of the primary tumour in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine-non-neuroendocrine neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33637345" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Does surgery provide a survival advantage in non-disseminated poorly differentiated gastroenteropancreatic neuroendocrine neoplasms?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36227392" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Surgical Management of G3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35380711" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Survival According to Primary Tumor Location, Stage, and Treatment Patterns in Locoregional Gastroenteropancreatic High-grade Neuroendocrine Carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35380711" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Survival According to Primary Tumor Location, Stage, and Treatment Patterns in Locoregional Gastroenteropancreatic High-grade Neuroendocrine Carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32556871" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Impact of Postoperative Chemotherapy on the Survival of Patients with High-Grade Gastroenteropancreatic Neuroendocrine Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31478977" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Adjuvant Chemotherapy Versus Observation Following Resection for Patients With Nonmetastatic Poorly Differentiated Colorectal Neuroendocrine Carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30706232" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Survival in Patients with High-Grade Colorectal Neuroendocrine Carcinomas: The Role of Surgery and Chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32323879" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Adjuvant chemotherapy for patients with gastric neuroendocrine carcinomas or mixed adenoneuroendocrine carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34787737" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Prognosis for Poorly Differentiated, High-Grade Rectal Neuroendocrine Carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22473169" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23591432" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Consensus guidelines for the management and treatment of neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22819619" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Chemotherapy in gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC): a critical view.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32293725" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Etoposide and cisplatin versus irinotecan and cisplatin as the first-line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: A randomized phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35980649" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28522174" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21456005" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22973169" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8935599" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Somatostatin analogue treatment of neuroendocrine tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25770151" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34342086" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36739879" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22940375" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22940375" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25662891" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Treatment of High-Grade Metastatic Pancreatic Neuroendocrine Carcinoma with FOLFIRINOX.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25157273" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Topotecan monotherapy in heavily pretreated patients with progressive advanced stage neuroendocrine carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Pembrolizumab (P) monotherapy in patients with previously treated metastatic high grade neuroendocrine neoplasms (HG-NENs)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32152503" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Activity&amp;Safety of Spartalizumab (PDR001) in Patients (pts) With Advanced Neuroendocrine Tumors (NET) of Pancreatic (Pan), Gastrointestinal (GI), or thoracic (T) origin,&amp;gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35504244" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Avelumab in unresectable/metastatic, progressive, grade 2-3 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33882143" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34973511" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31672771" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Epigenetic EGFR Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Nivolumab plus platinum-doublet chemotherapy as first-line therapy in unresectable, locally advanced or metastatic G3 neuroendocrine Neoplasms (NENs) of the gastroenteropancreatic (GEP) tract or unknown (UK) origin: Preliminary results from the phase II NICE-NEC trial (GETNE T1913)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Nivolumab (nivo)±ipilimumab (ipi) in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) (GCO-001 NIPINEC)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25465415" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Microsatellite unstable gastrointestinal neuroendocrine carcinomas: a new clinicopathologic entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27048246" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24763982" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : A retrospective review of 126 high-grade neuroendocrine carcinomas of the colon and rectum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1847579" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Small cell carcinomas of the large intestine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2546989" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Small cell carcinoma of the colon. A case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11871823" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Long-term survival in advanced small cell carcinoma of the colorectum: report of a case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24412088" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Long term outcomes of neuroendocrine carcinomas (high-grade neuroendocrine tumors) of the colon, rectum, and anal canal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28130474" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Design and Validation of the GI-NEC Score to Prognosticate Overall Survival in Patients With High-Grade Gastrointestinal Neuroendocrine Carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28232598" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21709192" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29602973" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32700133" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Temozolomide alone or in combination with capecitabine in patients with advanced neuroendocrine neoplasms: an Italian multicenter real-world analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33496040" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Treatment Outcomes of Well-Differentiated High-Grade Neuroendocrine Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33923759" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Multicenter Analysis of Treatment Outcomes for Systemic Therapy in Well Differentiated Grade 3 Neuroendocrine Tumors (NET G3).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25155459" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Surgical resection provides an overall survival benefit for patients with small pancreatic neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26984415" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Pathology and Surgical Treatment of High-Grade Pancreatic Neuroendocrine Carcinoma: an Evolving Landscape.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28894897" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30540557" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30115686" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29387927" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Investigation of receptor radionuclide therapy with 177Lu-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
